Official GapSummit 2016 Online Programme

4th - 6th April 2016Old Divinity School, St John’s College, Cambridge UK

connect

challengegrow

2016GapSummitSummit

çêÖ~åáëÉÇ=Äó=çêÖ~åáëÉÇ=Äó=

2

Sche

dule

3rd Aprilfrom 14:00 Arrivals at Trinity Hall

15:00 - 16:15 Registration atOld Divinity School

16:15 - 18:00 Welcome Workshop

18:00 - 19:00 Networking Reception

4th April08:00 - 08:45 Registration & Breakfast08:45 - 09:00 Welcome09:00 - 09:30 Sophie Kornowski-Bonnet09:30 - 11:00 Research & Innovation Gap

11:00 - 11:30 Refreshments11:30 - 12:45 Funding Gap12:45 - 13:45 Lunch13:45 - 14:15 Jeremy Levin14:15 - 15:30 Future Health Gap15:30 - 16:00 Refreshments16:15 - 17:00 LoT Workshop17:10 - 17:55 LoT Workshop18:00 - 19:00 Drinks Reception19:15 - 22:00 Formal Dinner & Address

Leszek Borysiewicz

5th April08:00 - 09:00 Registration & Breakfast09:00 - 09:30 Peder Holk Nielsen

09:30 - 10:45 Future Resources Gap

10:45 - 11:15 Refreshments11:15 - 11:45 Reginald Seeto11:45 - 13:00 People Gap13:00 - 14:00 Speakers’ Lunch13:00 - 19:00 LoT Field Trip

6th April08:00 - 09:00 Registration & Breakfast09:00 - 09:30 John Walker09:30 - 11:00 Bioethics Gap11:00 - 11:30 Refreshments11:30 - 12:45 Public Perception &

Education Gap12:45 - 13:45 Lunch13:45 - 16:00 Voices of Tomorrow Finals16:00 - 16:30 Refreshments16:30 - 16:45 Voices of Tomorrow Results16:45 - 17:00 Conclusion18:30 - 19:30 Ghost Tour19:30 - 22:00 Pub Dinner

7th Aprilby 09:30 Vacate Rooms at Trinity Hall10:00 - 12:00 Punting15:00 - 16:30 Walking Tourby 17:30 Departures

Global Biotech Revolution

@GlobalBRev#GapSummit#BiotechFuture

Global Biotech Revolution


3

Con

tent

s

Schedule 2

Overview 4

Welcomes 5

Programme 7

Speakers 13

Voices of Tomorrow Competition 44

Leaders of Tomorrow 53

Committee 62

Acknowledgements 67

Venue Details 68

Map 71

2016GapSummit


4

Ove

rvie

wResearch & Innovation Gap What are the biggest gaps in

biotechnology research and innovation,and how will this change by 2050?

Are we optimistic about the future?

Funding Gap What are the biggest gaps in fundingbiotech research and innovation,

and how should we best fill these?

Future Health Gap What are the major health challenges to be addressed by 2050, and what solutions

can biotechnology offer?

Future Resources Gap What are the major resource challenges we will face by 2050, and what solutions

can biotechnology offer?

People Gap What are the biggest humanresource needs in biotechnology?

How do we best attractand nurture talent?

Bioethics Gap Should we allow genome editing andmitochondrial DNA replacement in em-

bryos to prevent genetic diseases,and if so, where should we draw the line?

How should we regulate theprivacy of genetic data?

How can we prepare for and respond to future pandemics in an ethical way?

Public Perception &Education Gap

How does the publiccurrently perceive biotechnology?

How can we best engage the public to educate them about developments in

biotechnology, and whatare the biggest barriers?

The Global Biotech Revolution Executive welcomes you to the second GapSummit, held in

Cambridge, UK in April 2016. GBR is a not-for-profit organisation led by students and early-

stage professionals. Our mission is to support the next generation of leaders who will ensure the

sustainability and growth of the global bio-economy. We connect Leaders of Today to Leaders of

Tomorrow in biotechnology, through global debate platforms and online engagement. We ask all

invited to use this unique platform to “Connect, Grow and Challenge” people, ideas, knowledge

and development gaps in global biotechnology.


2016GapSummit 5

Wel

com

e

A note from the GapSummit 2016 Committee

Welcome to Global Biotech Revolution’s international and intergenerationalleadership summit in biotechnology.

The GapSummit conference will allow you to discuss the currentchallenges facing global biotechnology between now and 2050, and to develop

solutions to these.

Congratulations to our Leaders of Tomorrow on being selected through a highly competitive application process. You are joining us from over forty nations across

six continents. We wish you the best as you embark upon an opportunity of a lifetime: debating and developing solutions to challenges in biotechnology with the

Leaders of Today. We hope that the platform we are providing you with over the next few days will allow you to embody our core values of connecting,

growing and challenging.

During the summit, make the most of the interaction opportunities provided whilst reflecting on the changes, actions and impact you wish to bring

throughout your own careers.

The team is thankful for the advice and support we have received from the GBR Executive Team, GBR Advisory Board, Speak-ers and Sponsors who have helped build the GapSummit into

an intergenerational leadership forum for global biotechnology.


6

Wel

com

eA note from the GBR Advisory Board

“Biotechnology is about doing things in the real world, so many other skills are needed in addition to science and technology - including politics, management and business. It can take years to assemble these skills in individuals or teams, and it can take years for projects to come to fruition. It takes sustained energy to drive them. So I’m delighted at the focus of the conference on the young - they have both the energy and the time.”

Prof. Christopher Dobson Master of St. John’s College

University of Cambridge

Prof. Chris LoweFirst Director of Bioscience

Enterprise Programe

Tom SaylorNon-Executive Director

Arecor

Prof. Gerard EvanHead of Department of Biochemistry


Dr Annalisa JenkinsCEO

Dimension Therapeutics

Sir Gregory WinterAdvisory Board Chair

Master of Trinity CollegeUniversity of Cambridge


2016GapSummit 7

Prog

ram

me

DAY 0: 3rd April 2016Leaders of Tomorrow Welcome Day

from 14:00 Arrivals at Trinity Hall15:00 - 16:15 Registration at Old Divinity School, St. John’s College16:15 - 16:30 Welcome Workshop Introduction16:30 - 17:00 Welcome Workshop Session 1

1. PitchingProf. Alan Barrell, Entrepreneur in Residence, Judge Business School,University of Cambridge

2. Ideation & Growing Your EcosystemMiranda Weston-Smith

3. Ice-breakers

17:00 - 17:30 Welcome Workshop Session 2As Session 1 (groups to rotate)

17:30 - 18:00 Welcome Workshop Session 3As Session 1 (groups to rotate)

18:00 - 19:00 Networking Reception


8

Prog

ram

me

DAY 1: 4th April 2016

08:00 - 08:45 Registration and Breakfast08:45 - 09:00 Welcome

Lisa Altmann-Richer, President, GapSummit 201609:00 - 09:30 Keynote

Dr Sophie Kornowski-Bonnet, Global Head of Roche Partnering,F. Hoffmann-La Roche

09:30 - 11:00 Research and Innovation GapPanel Discussion

Chair: Prof. Jackie Hunter CBE, CEO Stratified Medical

Sir Gregory Winter, Master, Trinity College, University of Cambridge

Dr Virginia Acha, Executive Director, Research, Medical and Innovation,Association of the British Pharmaceutical Industry

Research & Innovation Showcase

Adina Mangubat, CEO, Spiral Genetics

Matthew Scholz, CEO, Immusoft

Dr Stanley Hirsch, CEO, FuturaGene Group

Dr Zahra Jawad, Team Leader in Antibody Phage Display, Agenus

Dr Emma Sceats, CEO, CN Bio Innovations

11:00 - 11:30 Refreshments11:30 - 12:45 Funding Gap

Panel Discussion

Chair: Matthew Scholz, CEO, Immusoft

Dr Francesco De Rubertis, Partner, Medicxi Ventures

Dr Deborah Harland, Partner, SR One

Dr Sam Fazeli, Senior Analyst & EMEA Head, Bloomberg Intelligence

Prof. Alan Barrell, Entrepreneur in Residence, Judge Business School,University of Cambridge


9

Prog

ram

me

12:45 - 13:45 Lunch13:45 - 14:15 Keynote

Dr Jeremy Levin, Chairman & CEO, Ovid Therapeutics14:15 - 15:30 Future Health Gap

Panel Discussion

Chair: Yvonne Sonsino, Partner & Innovation LeaderEurope & Pacific, Mercer

Dr Li Chen, President & CEO, Hua Medicine

Dr David Williams, CEO, Discuva

Urvashi Prasad, Director, Operation ASHA

15:30 - 16:00 Refreshments

16:15 - 17:00 Leaders of Tomorrow Workshops (Session 1)

1. Intellectual Property WorkshopJane Wainwright, Partner, Potter ClarksonMichael Pears, Partner, Potter ClarksonTom Harding, Senior Associate, Potter Clarkson 2. Commercialising Research WorkshopDr Sophie Kornowski-Bonnet, Global Head of Roche Partnering,F. Hoffmann La-RocheDr Nessa Carey, International Director, PraxisUnicoDr Robert Tansley, Investment Director, Healthcare, Cambridge Innovation Capital

3. Early Stage Business Development WorkshopFiona Nielsen, CEO at DNAdigest and RepositiveMainda Kiwelu, Strategist & Founder, ADNIAM HouseDr Shamus Husheer, CEO, Heartfelt Technologies Ltd

4. Communicating Science WorkshopJoanne Thomas, Projects & Events Officer, Sense About Science

5. Personalising Healthcare WorkshopProf. Jeff Evans, Professor & Director, Institute of Cancer Sciences, University of GlasgowProf. Richard Barker, Director, CASMI & Chairman, Precision Medicine CatapultDr Chris Torrance, CEO, PhoreMost Ltd

17:10 - 17:55 Leaders of Tomorrow Workshops (Session 2)As Session 1 (groups rotate)

18:00 - 19:00 Pre-dinner drinks (Trinity College Master’s Lodge)

19:15 - 22:00 Grand Dinner (Great Hall, Trinity College) with keynote byProf. Sir Leszek Borysiewicz, Vice-Chancellor, University of CambridgeDress code: business wear


10

Prog

ram

me

DAY 2: 5th April 201608:00 - 09:00 Breakfast09:00 - 09:30 Keynote

Dr Peder Holk Nielsen, President & CEO, Novozymes09:30 - 10:45 Future Resources Gap

Panel Discussion

Chair: Prof. Alison Smith, Department of Plant Sciences,University of Cambridge

Dr Stanley Hirsch, CEO FuturaGene

Dr Michiel van Lookeren Campagne, Head of Biology Research, Syngenta

Clare Wenner, Head of Renewable Transport, Renewable Energy Association

Prof. George Lomonossoff, Project Leader, Biological Chemistry, John Innes Centre

10:45 - 11:15 Refreshments11:15 - 11:45 Keynote

Dr Reginald Seeto, Vice President, Head of Partnering & Strategy, MedImmune

11:45 - 13:00 People GapPanel Discussion

Chair: Tarquin Bennett-Coles, Client Partner, Euromedica

Fiona Cicconi, Executive Vice President, Human Resources, AstraZeneca

Adina Mangubat, CEO, Spiral Genetics

Richard Acton, Operations Director, SRG

Dr Brindan Suresh, Partner, McKinsey & Company

13:00 - 14:00 Speakers’ Lunch13:00 - 18:00 Leaders of Tomorrow Field Trip

Dr Charlotte Whicher, Product Manager, RepositiveDr Allen Eaves, CEO, STEMCELL TechnologiesGraham Clarke, CEO, ImmBioDr Marianne Brüggemann, Director of Research, Recombinant Antibody TechnologyDr Marcus Yeo, CEO, DefiniGENEmily MacKay, CEO, CrowdsurferDr Nadia Shivji, Events & Business Development Manager, One NucleusNadine Su, Marketing Director, MedTech InternationalDavid Gill, Managing Director, St. John’s Innovation CentreDr Thomas Mander, COO, DomainexDr Wei Li, Co-Founder, MORPHOGEN-IXDr Chibeza Agley, Founder & CEO, CamBioScienceSarah Haywood, CEO, MedCitySir Gregory Winter, Master, Trinity College, University of Cambridge


11

Prog

ram

me

DAY 3: 6th April 201608:00 - 09:00 Breakfast09:00 - 09:30 Keynote

Prof. Sir John Walker, Nobel Laureate & Emeritus Director,MRC Mitochondrial Biology Unit

09:30 - 11:00 Bioethics GapPanel Discussion

Chair: Dr Silvia Camporesi, Lecturer in Bioethics & Society,King’s College London

Prof. John Harris, Lord David Alliance Professor of Bioethics, University of Manchester

Mr Tim Child, Medical Director & HFEA Person Responsible, Oxford Fertility

Dr Lenias Hwenda, Founder, Medicines for Africa

Prof. Tim Lewens, Professor of Philosophy of Science, University of Cambridge

Dr Federica Lucivero, Marie Curie Fellow, King's College London

11:00 - 11:30 Refreshments11:30 - 12:45 Public Perception and Education Gap

Panel Discussion

Chair: Lisa Melton, Senior News Editor, Nature Biotechnology

Simon Burall, Director, Involve

Anna Perman, Communities Manager, British Science Association

Dr Tim Guilliams, CEO, Healx

Dr Ipshita Mandal, President, Global Biotech Revolution

12:45 - 13:45 Lunch13:45 - 16:00 Voices of Tomorrow Competition

Chair: Dr Judith Dunn, Vice President, Global Head of ClinicalDevelopment & Head of Roche Innovation Center, New York

Judges: Dr Cathy Prescott, Founder Director, BiolatrisMark Goodson, Lead Business Advisor, Social Incubator EastDr Robert Tansley, Cambridge Innovation CapitalDr Matthias Evers, Director, McKinsey & Company

16:00 - 16:30 Refreshments16:30 - 16:45 Winners Announced16:45 - 17:00 Conclusion

çêÖ~åáëÉÇ=Äó=çêÖ~åáëÉÇ=Äó=çêÖ~åáëÉÇ=Äó=çêÖ~åáëÉÇ=Äó=

12

Prog

ram

me

Post GapSummit: 6th & 7th April 2016

6th April

18:30 - 19:30 Ghost Tour19:30 - 22:00 Pub Dinner

7th April

by 09:30 Vacate rooms at Trinity Hall08:30 - 09:30 Store luggage at Old Divinity School10:00 - 12:00 Punting12:00 - 15:00 Informal Lunch15:00 - 16:30 Walking Tour of Cambridgeby 17:30 Final Departures


13


Key

note

Spe

aker

s

Sophie Kornowski-Bonnet, PhD, is Global Head of Roche Partnering and a member of the Roche Corporate Executive Committee, based at Roche’s headquarters in Basel, Switzerland. Her career has taken her from Paris to New York, via Chicago. She began at Abbott Diagnos-tics in France, first in regulatory affairs, then moved to Abbott Pharmaceuticals in Chicago and was in Market Research, then Medical Representative in NYC. For four years in the USA and then two years in France, she held positions in Strategic Marketing and as Business Unit Head, Neuroscience for Sanofi Winthrop. She further pursued her professional career within the Merck-Sharp & Dohme Group as Head of Strategic Planning, France, before relocating to Israel as General Manager to create and develop the affiliate for the group, subsequently holding respectively the functions of Vice-President of Rheumatology and Analgesia in the US, then Rheu-matology and Cardiology head for France. She joined Roche France in March 2007 as General Manager, and was then appointed Head of Roche Partnering in Febru-ary 2012. She holds a PhD in pharmacy from the Faculty of Pharmacy in Paris, France, and an MBA in Marketing and Finance from the University of Chicago. She also has the distinction of having been inducted into the French Legion of Honor (Ordre national de la Légion d’honneur) by the French Minister of Research in recognition of her achieve-ments. In 2014, FierceBiotech named Sophie one of the Top Women in Biotech.

Dr Sophie Kornowski-BonnetGlobal Head of RochePartneringF. Hoffmann La-Roche

Dr Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, Inc., a private company developing novel medicines for orphan diseases of the brain. Dr Levin has extensive experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. He has been voted one of the 25 most influential people in the biopharmaceuti-cal industry. Prior to Ovid, Dr Levin served as Presi-dent and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Previously, he was a member of the Exec-utive Committee of Bristol-Myers Squibb (NYSE:BMY) where he had global responsibilities for strategy, alliances and transactions. In this role, he devised and led the BMY’s “String of Pearls” strategy, which resulted in the transformation of the company. Prior to BMY, he was Global Head of Strategic Alliances at Novartis (NYSE: NVS). In this role, he established and managed strategic collaborations with multiple companies around the world. Dr Levin has served on a number of public and private company boards over the years, and currently serves on the Board of Directors of BioCon, Ltd (NSE: BIOCON) and privately held ZappRx. Dr Levin is the recipient of a number of awards including the Kermode Prize for work on novel hypertension drugs, the Albert Einstein Award for Leadership in Life Sciences, the B’nai B’rith Award for Distinguished Achievement for commitment to improving global health care and the Officer’s Cross of the Order of Merit of the Republic of Hungary.

Dr Jeremy LevinChairman & CEOOvid Therapeutics


14

Professor Sir Leszek Borysiewicz was installed as the 345th Vice-Chancellor of the University of Cambridge

on 1 October 2010. The Vice-Chancellor is the principal academic and administrative officer of the University. Sir

Leszek was previously Chief Executive of the UK’s Medical Research Council (2007-10). From 2001 to 2007 he was

at Imperial College London, as Principal of the Faculty of Medicine and later as Deputy Rector, responsible for the

overall academic and scientific direction of the institu-tion. He led the development of inter-disciplinary research

between engineering, physical sciences and biomedicine. In 1988 he was a Lecturer in Medicine at Cambridge. He

went on to be Professor of Medicine at the University of Wales in Cardiff, where he led a research team that carried out pioneering work on vaccines. In particular, his unit in Cardiff conducted clinical trials for a therapeutic vaccine

for human papillomavirus (a cause of cervical cancer) – the first in Europe. He was knighted in 2001 for services to

medical research and education. He was a founding Fellow of the Academy of Medical Sciences in 1996 and a member of its Council from 1997 until 2002; and he became a

Fellow of the Royal Society in 2008.

Prof. Sir Leszek BorysiewiczVice-Chancellor


In April 2013, Peder Holk Nielsen, born 1956, took over as the second CEO of Novozymes since its IPO. Peder has

dedicated his career to the field of industrial biotechnology, beginning in 1984 as a Product Manager in the Enzymes

Division of Novo A/S. Through the years, Peder has worked in many different parts of the business, not only shaping

the company as it is today but also solidifying the market insight and research capabilities that will foster Novozymes

of tomorrow. Peder’s career path quickly took him into a succession of leadership roles. From 1987 he became Head of the New Business Development Group. He took over as

Vice President in R&D in 1990. In 1995 Peder joined the management team of the enzyme business in Novo Nordisk A/S initially as Vice President of Development and Quality

management, and from 1999 he led Sales and Marketing in the enzymes business. He held this position until the

demerger of Novozymes from Novo Nordisk. With the creation of Novozymes in 2000, Peder continued running the operational

side of the business as Executive Vice President, responsible for sales, marketing and supply chain activities. In 2007, he assumed leadership for all of Enzyme Business,

including production, procurement, development and quality management. During his many years in the management teams of the Novozymes business, Peder has focused

his attention on developing the organization and processes to effectively turn customer insights into product ideas and deliver solutions that excite Novozymes’ customers.

Often he has been directly involved in leading such ventures as was the case when Novozymes built its partnerships in biomass conversion. Peder serves on the Board

of Directors of Hempel A/S, a leading developer and supplier of coatings, and of LEO Pharma A/S, a leading company in dermatological and thrombotic treatments.

Dr Peder Holk NielsenPresident & CEO

Novozymes

Key

note

Spe

aker

s


15

Dr Seeto joined the MedImmune team in 2008, and has held a number of leadership positions with the company during his tenure. In 2013, he assumed his current role on MedImmune’s executive team, in which he formed, and now leads, the company’s Partnering and Strategy Department. This group is responsible for devising and executing MedImmune’s external partnership strategy, including business development activities – from M&A and licensing to co-development, joint ventures and out-licensing - along with academic, government and non-profit collaborations and alliances to support all of MedImmune’s biologics and therapy area strategies. Seeto originally joined MedImmune as Vice President of Global Strategic Marketing and Portfolio Management where he worked closely with the R&D leadership team. He was later promoted to MedImmune’s executive team, as EVP of the Corporate Development and Strategy Group, which included the following departments: business develop-ment, corporate strategy, corporate projects, MedIm-mune Ventures and portfolio management. Prior to MedImmune, Seeto was Vice President of Global Marketing for Schering Plough/Organon Biosciences and Executive Director of US Marketing for Boehringer Ingelheim Pharma-ceuticals. Earlier in his career he was a consultant at McKinsey & Company and started his career as a medical doctor involved in both clinical practice and research.

Dr Reginald SeetoVice President,Head of Partnering &StrategyMedImmune

Professor Sir John Walker FRS studied chemistry at St Catherine’s College Oxford. After periods of study and research at the University of Wisconsin USA, and The Pasteur Institute in Paris, in 1974 he joined the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, where he established the details of the modi-fied genetic code of mitochondria, helped to discover overlapping genes in bacteriophages and discovered the two eponymous protein sequence motifs involved in binding nucleotides. They are the most widely dispersed motifs in the entire biological kingdom. Here, he also developed his interest in how energy in food is converted into the molecule ATP, the energy currency of life. In 1994, his work led to the realisation that in a complex molecular machine in our bodies, the energy released by the oxidation of dietary sugars and fats is coupled by a mechanical rotary mechanism to the chemical synthesis of ATP. This work led to the award of the Nobel Prize in Chemistry in 1997. In 1998, he was appointed Director of the MRC Dunn Human Nutrition Unit in Cambridge, which became the MRC Mitochondrial Biology Unit in 2008. Since 2013 he has been Director Emeritus. Here he continues to delve deeper into the fundamental basis of energy conversion in biology. He is a Fellow of the Royal Society, and in 2012, he received its Copley Medal, the UK’s highest scientific accolade. He is also a Fellow of the Academy of Medical Sciences, a Fellow of Sidney Sussex College, Cambridge, a Foreign Member of L’Accademia Nazionale dei Lincei, the Royal Netherlands Academy of Arts and Sciences, The Royal Society of New Zealand and a Foreign Associate of the US National Academy of Sciences.

Prof. Sir John WalkerNobel Laureate & Emeritus DirectorMRC Mitochondrial Biology Unit

Key

note

Spe

aker

s


16

Res

earc

h an

d In

nova

tion

Gap

Jackie Hunter is the Chief Executive Officer of Stratified Medical. Stratified Medical unites traditional pharmaceuti-

cal development methodology with powerful predictive analytical capabilities to augment the research capabilities

of its drug scientists so that they can gain new insights to increase the efficiency of medicines development.

Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry in-

cluding leading neurology and gastrointestinal drug discov-ery and early childhood development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life

science sector in harnessing the power of open innovation and most recently was chief executive of the Biotechnology

and Biological Sciences Research Council (BBRSC). She holds a personal chair from St George’s Hospital Medical School, which was awarded in recognition of her contri-bution to bioscience research and was awarded the 2015

AstraZeneca prize in Pharmacology.

Prof. Jackie Hunter CBECEO

Stratified Medical

Sir Gregory Winter FRS is Master of Trinity College Cambridge and until recently a member of the Medical

Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist, inventor and entrepreneur. His work has involved the development of technologies for making pharmaceutical antibodies by genetic engineering. Such antibodies have proved useful for treatment of cancer

and immune disorders, and now comprise many of the world’s top selling pharmaceutical drugs. In order to see his technologies applied, Sir Gregory founded Cambridge An-tibody Technology and Domantis (both acquired in 2006),

and most recently Bicycle Therapeutics, which is developing a peptide product for treatment of cancer.Sir Gregory Winter

MasterTrinity College,



2016GapSummit 17


Res

earc

h an

d In

nova

tion

Gap

Virginia (Ginny) has worked in private sector and aca-demia throughout her career, combining her interests in science policy research and innovation performance within and across organizations. She joined ABPI in 2015 to lead the organisation’s policy efforts for research, medical and innovation opportunities that will lead to better treatment for patients. Ginny is the senior ABPI lead for the association’s work on biologics, including biosimilars. Ginny previously worked for Amgen as Director, Global Regulatory and R&D Policy – Europe, Middle East and Africa. Previously, she spent nearly five years at Pfizer working on policy development and en-gagement in science, innovation and access and choice in healthcare. Ginny joined biopharma after a decade in academia where she held posts on innovation strategy at Imperial College Business School, the Science Policy Research Unit (SPRU), and the Centre for Research in Innovation Management (CENTRIM), as well as a post-doc role at London Business School. She is a Visit-ing Researcher in the Innovation & Entrepreneurship Department at Imperial College Business School.

Dr Virginia AchaExecutive Director Research, Medical & InnovationAssociation of the British Pharmaceutical Industry(ABPI)


18

Res

earc

h an

d In

nova

tion

Gap

Adina Mangubat is CEO and co-founder of Spiral Genet-ics, a Seattle-based bioinformatics company that develops

high performance software for next generation sequencing data, particularly for medical, pharmaceutical, and agri-cultural research. Adina was featured in Forbes 2013 “30

Under 30” for Science and Healthcare, was recognized by the Washington Biotechnology and Biomedical Associa-tion as one of the 2013 Women to Watch in Life Science,

and was a keynote panelist at the 2013 BIO conference in Chicago. Adina’s passion for world-changing technology,

coupled with her adept entrepreneurial focus and team development skills have enabled her to bring Spiral Genet-

ics to the forefront of bioinformatics innovation. Prior to founding Spiral Genetics, she also worked with

two other high technology start-ups. A passionate mentor for young innovators, Adina co-founded DragonCurve, an

organization dedicated to supporting young entrepreneurs.

Adina MangubatCEO

Spiral Genetics

Matthew Scholz is Immusoft’s founder and Chief Executive Officer. His curiosity about how the body attacks invading pathogens and stores the information sparked his idea for

Immusoft. He realized that he could modify technology developed by Nobel Laureate David Baltimore to program

resting B cells to secrete therapeutic proteins. The modi-fied system is the core of Immusoft’s technology platform, Immune System Programming™. Immusoft, which under

Matthew’s leadership is transitioning from a research bio-tech to a clinical company, has raised capital from the U.S. National Institutes of Health, Peter Thiel’s Breakout Labs, Founders Fund Science, and prominent private investors, including Tim Draper and the former head of preclinical

development at Seattle Genetics. Matthew has a degree in computer science. He is a mentor for the Thiel Fellow-

ship, a program that awards grants to some of the brightest scientific minds in the world under age 20.

Matthew ScholzCEO

Immusoft

Dr Zahra JawadTeam Leader

Agenus

Zahra completed her PhD at the University of Cambridge in the Biochemistry Department in Protein Evolution,

attempting to evolve protein folds. After a brief post doc working on designing zinc finger proteins to bind unique

DNA structures, she spent almost 8 years at Domantis, then GSK designing antibodies for a vast array of therapeu-

tic indications like asthma, arthritis, cachexia and cancer. She continues working in the field of antibody therapeutics

leading a team initially at MRC Technology and now at Agenus in antibody phage display.


19

Res

earc

h an

d In

nova

tion

Gap

Dr Hirsch is the Group CEO of FuturaGene Ltd., a leader in plant genetic research and development for the global, sustainable industrial forest sector. Futura-Gene obtained the first ever commercial approval for yield enhanced genetically modified eucalyptus in April 2015. FuturaGene is a wholly owned subsidi-ary of Suzano Pulp and Paper of Brazil. Dr Hirsch has served as general manager of two diagnostics develop-ment companies and a drug development company, as well as director of business development for a group of healthcare companies. Early in his career, Dr Hirsch was involved in the development of automated systems for plant tissue culture. Dr Hirsch serves on the boards of Foamix (FOMX-NASDAQ), a specialty pharmaceuti-cal company and a research products company and has advised various venture capital funds. He received his D. Phil. from Oxford University and his B.Sc. (Med) Honours from the University of Cape Town.

Dr Stanley HirschCEOFuturaGene Group

Dr Emma Sceats obtained a DPhil in Chemistry from Oxford University after graduating from the Massa-chusetts Institute of Technology in 2004 (M.S. Chem-istry). She spent three years at Isis Innovation, Oxford’s technology transfer company, managing and licensing a diverse portfolio of IP and software developed at the University. Amongst more than 50 of her projects, encryption software that prevents so-called “man-in-the-middle” attacks, conceived and developed at Oxford with US military funding, is now the subject of a suc-cessful spin-out with offices in London and San Francis-co focusing on secure data transmission and payment protocols. Dr Sceats joined CN Bio Innovations in 2010 as Commercial Manager to spearhead the organisation’s sales, marketing and business development activities. She has led sales and partnering initiatives with major pharmaceutical organisations and overseen academic research and licensing programs, including with the Massachusetts Institute of Technology (MIT) that have led to the development of the company’s leading technologies and IP. She assumed the role of CEO in January 2016.

Dr Emma SceatsCEOCN Bio Innovations


20

Fund

ing

Gap

Prior to co-founding Medicxi Ventures, Francesco was with Index Ventures for 18 years, having joined in 1997 to launch its life sciences practice. While at

Index life sciences, he spearheaded the creation and adoption of the asset-centric investment strategy and

led the growth of the firm. At Medicxi he also oversees the firm’s operations. Francesco’s investments include

CellZome (acquired by GlaxoSmithKline), Egalet, GenMab, GenSight Biologics, Micromet (acquired by

Amgen), Minerva Neurosciences, Molecular Partners, PanGenetics (acquired by Abbott), Parallele Bioscienc-

es, Profibrix (acquired by The Medicines Company), Versartis and several others. Francesco received a BA

in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral

scientist at the Whitehead Institute, MIT.

Dr Francesco De RubertisPartner

Medicxi Ventures

Deborah joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One

extensive operational, drug development and licens-ing experience gained through numerous roles held

in clinical development, medical affairs and business development during her more than 20 year tenure in the pharmaceutical industry. Deborah is currently a member of the Board of Directors of Mission Thera-

peutics, Bicycle Therapeutics, Atopix Therapeutics, AtoxBio, f-star, VH Squared and Asceneuron. She

was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange,

2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on

the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons)

in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and

her MBA from Henley Management College.

Dr Deborah HarlandPartnerSR One


21

Fund

ing

Gap

Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Profes-sional service at BI. Dr Fazeli specializes in European pharmaceuticals and biotechnology. Dr Fazeli brings with him over 15 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Prior to joining Bloomberg in 2010, Dr Fazeli worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, Dr Fazeli was a research scientist for seven years. Dr Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a bachelor’s of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.

Dr Sam FazeliSenior Analyst& EMEA Head,Bloomberg Intelligence

Professor Alan Barrell, DBA., FRSA is Entrepreneur in Residence at the Centre for Entrepreneurial Learning, Judge Business School, University of Cambridge. He has spent some 30 years in senior executive positions in technology-based industries and has become one of Cambridge’s most articulate promoters of entrepre-neurship around the world. He has received a large number of honorary positions and is a lecturer in high demand at universities all over the world. Alan has been in invited to Lahti University of Applied Science as the first Honorary Research Fellow of the University.

Prof. Alan BarrellEntrepeneur in ResidenceJudge Business School,University of Cambridge


22

Futu

re H

ealt

h G

apYvonne rejoined Mercer in 2013, after 6 years out of the consulting industry working in senior HR roles in the Middle East and Europe. In her previous role in Mercer, Yvonne led the International Consulting

Group in London, working with global companies on HR policy and programme design. Her new role at

Mercer is Innovation Leader for the Europac region, leading design projects in the areas of Health, Wealth

and Careers. Yvonne is a member of the Regional Leadership Team in Mercer and externally Co-Chairs

the DWP Fuller Working Lives Business Strategy Group. She is a Fellow of The Pensions Management Institute and a previous author of their International

Diploma syllabus. Her own first book, The New Rules of Living Longer, was published in November 2015.

Yvonne has Masters Degrees in Psychology and Busi-ness Research, and volunteers in her spare time for a

national charity supporting nursing and health.

Yvonne SonsinoInnovation Leader,

EuropeMercer

Dr Li Chen is the co-founder and CEO of Hua Medicine, a Chinese biotech company focuses on discovery, development and commercialization of

clinically differentiated medicines for worldwide unmet medical needs. Hua Medicine currently has

world-wide rights to two novel assets. The most advanced program is a first-in-class, oral drug for the treatment of Type 2 Diabetes currently in Phase 2 tri-als in China. Before Li started Hua Medicine, he was

the Chief Scientific Officer at Roche R&D China and a member of Roche Pharma Research Leadership Team.

He was an adjunct professor at Tongji University. Li obtained a master’s degree in 1985 from East China Normal University in Shanghai where he also gave

lectures in Organic and Synthetic Organic Chemistry. Li completed his university education with a Ph.D. in Organic Chemistry from Iowa State University in the

United States in 1992.

Dr Li ChenPresident & CEO

Hua Medicine


23

Futu

re H

ealt

h G

ap

David has been working in the Pharmaceutical indus-try for over 30 years, passionately and directly involved in all aspects of drug discovery and development work-ing towards providing treatments for many diseases including new drugs marketed for infectious disease and cancer. Originally in banking, he retrained as a scientist going on to develop distinguished expertise in signal transduction and structural biology research having authored or co-authored over 70 significant publications and patents. As well as co-founding the successful Antibiotics Company, Discuva, in 2009, David also co-founded the disruptive therapeutics company, Bactevo and the AIM-listed Oncology drug discovery company Sareum and as part of the senior management steered Summit plc back to financial and scientific viability. Other major roles in UK/US senior management and research were performed at Millen-nium Pharmaceuticals, Medivir, Acambis and Roche.

Dr David WilliamsCEODiscuva

Before joining Operation ASHA as a Director, Urvashi led a multi-million dollar health portfolio of the Michael & Susan Dell Foundation in India focused on improv-ing the lives of the urban poor. During her tenure at the foundation, Urvashi catalysed school health programs that reached out to over 15 million children. She also formulated a school health implementation framework in collaboration with the Government and other stakehold-ers. Urvashi has worked as a consultant for the World Health Organisation and with the Partnership for Child Development, Imperial College London. Urvashi is also on the Governing Board of Partnership for TB Care & Control, India’s largest TB network. She is a World Economic Forum Global Shaper. Urvashi completed her Bachelors in Genetics from University of Birmingham followed by an MPhil in Bioscience Enterprise from Uni-versity of Cambridge and an MSc in Public Health from the London School of Hygiene & Tropical Medicine.

Urvashi PrasadDirectorOperation ASHA


24

Lead

ers

of T

omm

orw

Wor

ksho

ps

Michael read Natural Sciences (Biochemistry) at Cam-bridge University before obtaining a PhD in biochemistry at the same university, where Merck Sharp Dohme spon-sored his research. His research involved using metabolic

profiling techniques to study a childhood neurodegenera-tive disease. During his PhD, he authored several papers

in the field of functional genomics. Michael joined Potter Clarkson in 2006 and qualified as a Chartered Patent At-

torney and European Patent Attorney in 2010. During his qualification, Michael was awarded the Peter FitzGibbon

Memorial Award for obtaining the highest mark in one of his UK exams. Michael handles a wide range of biotechno-

logical subject matter and has particular expertise in the drafting and prosecution of patent applications concerning

immunotherapy, protein stability, gene therapy, meta-bolic profiling, drug delivery, and assay technologies. In addition to acting before the European Patent Office, he

has also managed the prosecution of several global patent portfolios, including applications in Australia, Canada, China, India, Japan and the US. Over recent years, Michael has developed experience in the niche area of Sup-

plementary Protection Certificates (SPCs, a form of IP that can provide an additional monopoly period beyond patent expiry for some medicinal and plant protection prod-

ucts). As well as authoring various articles on the topic, Michael has been involved in coordinating the prosecution of high profile SPC portfolios throughout Europe,

including a case that was referred to the Court of Justice of the European Union.

Michael PearsPartner

Potter Clarkson

Jane read genetics at the University of Wales, Swansea, choosing to specialise in the areas of human disease genet-

ics and gene therapy technologies. Jane was awarded the Genetics Prize for the highest finals examination marks.

Prior to realising that her career path lay in the patent profession, Jane spent two years studying medicine at

Oxford University. Jane joined Potter Clarkson in 2001 and became a partner in 2011. Jane has continued to

work in the field of biotechnology and deals with subjects including recombinant technology, antibody therapies,

drug screening assays and gene therapy technologies. She also handles patent applications in a number of bio-

technology and chemistry cross-over areas, in particular combined chemical-biotechnology assays for biological

sample assessment and the biological production of modi-fied chemical compounds. Jane provides commercially

relevant advice tailored to the needs and commercial goals of each client, be they a University, SME or multinational

corporation. Jane regularly advises her clients on all aspects of filing and prosecution strategy, as well as third party issues such as oppositions, third party observations and

due diligence investigations. In particular, she has considerable experience planning worldwide patenting strategies and co-ordinating their implementation before numer-ous patent offices, as well as directly representing clients at the European Patent Office. Jane has been involved in a number of due diligence projects relating to company and

IP acquisitions (for both acquirer and acquiree).

Jane WainrightPartner

Potter Clarkson


25

Lead

ers

of T

omor

row

Wor

ksho

ps

Tom studied genetics (BSc (Hons)) at the University of Nottingham, followed by an MSc in applied biomo-lecular technology at the same university. Subsequently, Tom spent four years as a research scientist in oncology bioscience at AstraZeneca before joining Potter Clarkson in 2009 where he now specialises in patents in the life sciences field. Tom has particular experience of obtaining patent protection in antibody technology and therapeu-tics, nucleic acid technology, drug screening and simple medical devices. He has also been involved in several pat-ent oppositions in the same subject areas.Tom qualified as a European Patent Attorney in 2012 and a Chartered UK Patent Attorney in 2013. In 2011, he was awarded the Nick Wilson Memorial Award for obtaining the highest mark overall in one of the UK qualifying exams.

Tom HardingSenior AssociatePotter Clarkson

Dr Nessa Carey is the International Director at PraxisU-nico, the networking and training organisation which represents technology transfer officers. Prior to taking on this role in 2014, she was a Senior Director at Pfizer, spe-cialising in generating new collaborations with academia. Nessa has 10 years experience in senior scientific roles in UK biotech companies, a career path she embarked on after leaving an academic position at Imperial College, where she is now a Visiting Professor. Perhaps a little bizarrely, she is also a former forensic scientist and briefly trained as a vet. Nessa has a PhD from the University of Edinburgh and is the author of the popular science books The Epigenetics Revolution and Junk DNA: A Journey Through The Dark Matter Of The Human Genome.

Dr Nessa CareyInternational DirectorPraxisUnico

Robert joined Cambridge Innovation Capital in January 2014 as Investment Director with a focus on life sciences and associated technologies. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clini-cal team for the regulatory approval of Valcyte®. Twelve years ago, Robert joined the Cambridge based company Arakis and worked as Medical Director until its £106m sale to Sosei Inc. Since that acquisition, Robert has been involved in a number of start-up companies including founding the malaria-focused company Treague, being founding CEO of the University of Copenhagen spin-out Avilex Pharma and being part of the founding manage-ment team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School.

Dr Robert TansleyInvestment Director, HealthcareCambridge Innovation Capital


26

Lead

ers

of T

omm

orw

Wor

ksho

ps

Mainda enjoys helping creators and entrepreneurs take new products and services to market. She has industry ex-

perience working in publishing, information technology, television, travel, education and professional services. She

has predominantly worked as a marketer in both start-ups and multi-national firms and has successfully supported

key business development initiatives in the UK, US, South America, Europe and Asia. Having a keen interest in

intellectual property issues, innovation and the creative industries, Mainda has been involved in various ventures,

mentoring individual practitioners as well as running a member network, hosting speaking programmes and ad-

vising on policy. In 2014, Mainda founded Adniam House helping clients protect, build and monetise their brand and other IP as part of their business plans. Mainda is

also active in a social enterprise start-up helping educate girls from challenging backgrounds in Kenya. She is also a

volunteer speaker for the fair trade charity Traidcraft.

Mainda KiweluStrategist and Founder

ADNIAM House

Fiona Nielsen, founder and CEO of DNAdigest and Re-positive, is a bioinformatics scientist turned entrepreneur. She has more than 15 years of experience in project man-agement and software development ranging from web ap-plications to scientific tools for genetic analysis. Fiona ex-perienced first-hand the disconnect between the amount

of genetic data generated versus the amount of data avail-able for research, through her work in both academia and industry. Whilst working as a bioinformatics scientist, she recognised that much the human genomic data produced

was of immense value in diagnosis of diseases, phar-maceutical discovery and research, but could never be

shared because no tools existed to share this information whilst maintaining data confidentiality and privacy in an

easy and efficient way. She became increasingly frustrated that the knowledge carried in the huge quantities of data

that she generated and analysed – often related directly to specific diseases –was, effectively, wasted. Realising the urgency for data access to enable

genetic research and diagnostics, she left her job at Illumina to change the status quo and founded DNAdigest as a charity and Repositive as a social enterprise to enable faster and more efficient ethical data sharing for genetics. In 2015 Fiona was an invited speaker for

the International Conference of Genomics by BGI in the Community Genomes track, she was a panelist at the BioData World Congress and she was featured as a Rising Star in the

Movers and Shakers of BioBusiness at the BioBeat conference in Cambridge, UK.

Fiona NielsenCEO

DNAdigest & Repositive


27

Lead

ers

of T

omor

row

Wor

ksho

ps

Dr Shamus Husheer is the inventor of the technology behind DuoFertility and was for the first 6 years the CEO/CTO of Cambridge Temperature Concepts, the company that developed the product. DuoFertility is a new wear-able device and service to help couples conceive without drugs or surgery, and has been shown to be equally effective as a cycle of IVF after just six months of use. Shamus has 15 years of experience in developing instru-mentation and sensors during his MSc, PhD, and several Angel and VC-backed companies. He finally graduated his PhD at Cambridge after a group of investors said “we have the money to fund this, just graduate and do it!”, and proceeded to develop a digital health medical device before the first iPhone existed, taking the idea from sheet of paper through prototypes, medical approvals, trials and first sales all within 18 months. A “Recidivist Entrepre-neur”, Shamus has started companies in the chemical, medical, optical, finance and modelling industries and is now at it again with his new digital health company, HeartFelt Technologies, addressing the problem of chronic heart failure in casually compliant patients.

Dr Shamus HusheerCEOHeartfelt Technologies

Joanne joined Sense About Science in January 2015 as Projects and Events Officer. She shares responsibility for planning the annual reception and lecture, and workshops for the VoYS network. She is also supporting the new editions of Making Sense of Screening and Testing. Prior to joining the team, Joanne completed a Masters degree in Science Communication at the University of the West of England, where her dissertation focused on the role of public relations within science journalism. Before this, she volunteered at the Science Museum and At-Bristol Science Centre and worked at the Science Media Centre, a press office that aims to improve media coverage of sci-ence. Joanne also has an undergraduate degree in Biologi-cal Sciences from the University of Oxford.

Joanne ThomasProjects & EventsOfficerSense About Science


28

Lead

ers

of T

omm

orw

Wor

ksho

psProfessor Jeff Evans is a Group Leader (Translational

Cancer Therapeutics Laboratory) at the CR-UK Beatson Institute, Glasgow, Professor of Translational Cancer

Research and Director of the Institute of Cancer Sciences, University of Glasgow, and Honorary Consultant in

Medical Oncology at the Beatson West of Scotland Can-cer Centre, Glasgow. He is also the Lead of the Glasgow

Experimental Cancer Medicine Centre (ECMC). His initial medical training was at St Bartholomew’s Hospital

Medical School, University of London, and he trained in Medical Oncology at Charing Cross and St. George’s Hospitals, London. He is a Fellow of the Royal College of Physicians and Surgeons of Glasgow, a Fellow of the

Royal College of Physicians, Edinburgh, and of the Royal College of Physicians, London. His research interests

are in the pre-clinical and clinical development of novel anti-cancer agents, and his clinical interests are in Upper

GI Cancers and Melanoma, and he leads the Phase I clinical trials and drug development team in Glasgow. He has been an investigator in

numerous clinical trials in immuno-oncology. He is a member of the NCRN Upper GI Cancer Pancreatic Cancer and Gastro-Oesophageal Cancer sub-groups, member of the

ECMC – Industry Combinations Alliance Joint Steering Committee, former member of Cancer Research UK’s New Agents Committee, and former Chair of the UICC

(International Union against Cancer) International Cancer Research, Education, and Technology Transfer programme. He is co-editor of the clinical research section of the

British Journal of Cancer.

Richard is Director of the Oxford-UCL Centre for the Ad-vancement of Sustainable Medical Innovation (CASMI),

a major UK initiative aimed at transforming the R&D and regulatory processes in life sciences to bring advances

more rapidly and affordably to patients. He was recently appointed as chair of the Precision Medicine Catapult,

forging a national strategy in this rapidly developing field. He is also chairman of the South London Academic

Health Science Network, accelerating innovation in this region of the NHS, and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK

company using MRI to quantify the impact of therapy on disease. He is a board member of Celgene, a major US-

based bio-therapeutics company and of iCo Therapeutics, a Canadian bioscience company. His 25-year business career in healthcare has spanned biopharmaceuticals,

diagnostics and medical informatics – both in the USA and Europe. Most recently he was Director General of

the Association of the British Pharmaceutical Industry, Board member of EFPIA (the European industry association) and Council member of IFPMA (the international equivalent). As a co-founder of Life Sciences UK, member of the NHS Stakeholder

Forum, vice-chair of the UK Clinical Trials Collaboration and in many other roles, he has advised successive UK governments on healthcare issues, especially those relating to

developing, valuing and using new healthcare technologies.

Prof. Richard BarkerChairman

Precision Medicine Catapult

Prof. Jeff EvansDirector

Institute of CancerSciences, Glasgow


29

Lead

ers

of T

omor

row

Wor

ksho

ps

Dr Chris Torrance is a cancer researcher and entrepre-neur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of new and improved ‘Personalized Medicines’, including the identification of novel drug targets for pharmaceuti-cal development. By 2014 Dr Torrance and his colleagues had built Horizon into the fastest growing Biotech company in the UK. In the same year, the company listed on the London Stock Exchange with over 100 commer-cial and scientific staff and significant deal-flow with the pharmaceutical Industry, for which Horizon received the Queens Award for International Trade in 2012. Previous-ly, Dr Torrance was Head of Oncology and Biology at the UK Biotechnology company Vernalis PLC (LSE: VER), where he was responsible for progressing several novel kinase oncology programs. Dr Torrance has a bachelor’s degree in Biomedical Technology from Sheffield Polytechnic; a PhD in Biochemistry from East Carolina University (U.S.A) and completed Post-Doctoral training in the laboratory of Professor Bert Vogelstein at the Johns Hopkins University (U.S.A), where he pioneered the use of ‘X-MAN’ isogenic disease models in high-throughput screening and drug discovery. In 2014, Dr Torrance and Dr Venkitaraman (Cambridge University) founded PhoreMost Ltd to develop a new technology platform solution to the next big issue in delivering Per-sonalized Medicine, which is developing a toolbox of therapies big enough and affordable enough to impact the diverse array of key targets in cancer and other complex diseases, most of which are intractable to current drug discovery technologies.

Dr Chris TorranceCEOPhoreMost


30

Futu

re R

esou

rces

Gap

Alison Smith is Professor of Plant Biochemistry in the Department of Plant Sciences at the University of

Cambridge. Her research interests are focussed around the metabolism of plants, algae and bacteria, in par-

ticular of vitamins and cofactors, and more recently for compounds of commercial interest such as high-value

compounds and biofuel precursors. Current projects include taking a synthetic biology approach to develop-

ing microalgae as industrial biotechnology platforms to facilitate predictable metabolic engineering, and the

role of vitamins in the interaction of algae with other microbes in the environment. She has interacted with industry throughout her career, from agrichemical to oil companies to small start-ups, seeking to promote ways in which her research could be of use to them,

and was a founding member of the Algal Biotechnology Consortium in 2007.

Prof. Alison SmithDepartment of Plant Scienes


Michiel van Lookeren Campagne received his MSc in Biology, followed by a PhD in Developmental Biology

from Leiden University in the Netherlands for studying the development of cellular slime molds. He then spent

five years in New York, USA starting as post-doc and ending as Assistant Professor at Columbia University working on signal transduction in cancer. In 1993 he

returned to the Netherlands, where he started working on plant development at Plant Research International in

Wageningen. In 1999 he moved to industry and joined Aventis CropScience (now Bayer CropScience) starting

as Team Leader Reproductive Biology, and ending as Head of Research for Bayer CropScience - BioScience.

In 2009 Michiel joined Syngenta as Head of Biotechnol-ogy, based in Research Triangle Park, North Carolina,

USA. In 2014 he was appointed Head Biology Research for Syngenta, based in RTP.

Dr Michiel van Lookeren Campagne

Head ofBiology Research

Syngenta


31

Futu

re R

esou

rces

Gap

A graduate of Cambridge University, Clare worked for 10 years in the UK Ministry of Agriculture, Fisheries and Food in London. She then spent 10 years with a well-known lobbying company in London, specialising in agriculture, food and international trade issues and setting up the company’s operations in Brussels. After 4 years as Corporate Affairs Director in the private sector, Clare set up her own consultancy and now works for the Renewable Energy Association as Head of Renewable Transport as well as other clients. For the last 10 years Clare has majored on the development of renewable transport fuels in the UK and has been very closely involved with the implementation in the UK of the EU Renewable Energy and Fuel Quality Directives.

Clare WennerHead of Renewable TransportRenewable Energy Association

Dr Hirsch is the Group CEO of FuturaGene Ltd., a leader in plant genetic research and development for the global, sustainable industrial forest sector. Futura-Gene obtained the first ever commercial approval for yield enhanced genetically modified eucalyptus in April 2015. FuturaGene is a wholly owned subsidi-ary of Suzano Pulp and Paper of Brazil. Dr Hirsch has served as general manager of two diagnostics develop-ment companies and a drug development company, as well as director of business development for a group of healthcare companies. Early in his career, Dr Hirsch was involved in the development of automated systems for plant tissue culture. Dr Hirsch serves on the boards of Foamix (FOMX-NASDAQ), a specialty pharmaceuti-cal company and a research products company and has advised various venture capital funds. He received his D. Phil. from Oxford University and his B.Sc. (Med) Honours from the University of Cape Town.

Dr Stanley HirschCEOFuturaGene Group


32

Futu

re R

esou

rces

Gap

George Lomonossoff graduated from the University of Cambridge in 1976 and studied for his His Ph.D. at

MRC Laboratory of Molecular Biology (LMB), Cam-bridge. He moved to the John Innes Centre, Norwich

in 1980 and has continued to work there ever since apart from two periods of sabbatical leave in the USA.

George's research has focused on the molecular biology of RNA plant viruses and their use in bio- and nanotech-

nology. In recent years his research has involved the de-velopment of efficient transient expression technologies

for the rapid production of high value proteins in plants. He is an honorary professor at the University of East Anglia and has co-ordinated several EU Framework

consortia. In 2012 he was named “BBSRC Innovator of the year” for his work on plant-made pharmaceuticals

and in 2015 delivered the Society of General Microbiol-ogy Colworth Prize Lecture.

Prof. George LomonossoffProject Leader,

Biological ChemistryJohn Innes Centre


33

Peop

le G

ap

Tarquin Bennett-Coles is based in the Euromedica London office. He has just under two decades of life science executive search and interim management experience and has recently been working in partner-ship with biotech, digital health and rare and orphan disease SMEs as they commercialise across Europe and North America. He handles senior general management, C-Suite and board level roles within the commercial, medical, clinical, HR and country management func-tions of biotech, medtech, informatics, pharmaceutical, diagnostics and allied technology businesses. In addition he has partnered with, and supported, relevant industry associations, the VC community and the not-for-profit sector. He is a contributor to industry journals and has been invited to speak at international conferences on talent management. Tarquin is a trained STEM and SIP (Science Industry Partnership) Ambassador and has been a lecturer on the prestigious Masters in Bioscience Enterprise programme on behalf of Cambridge Univer-

Tarquin Bennett-ColesClient PartnerEuromedica

Fiona Cicconi joined AstraZeneca in September 2014 as Executive Vice-President, Human Resources. She started her career at General Electric where she held various human resources roles within the Oil & Gas business, which included experience in major global acquisitions and driving change. Subsequently, Fiona spent a number of years at Cisco, overseeing human resources in seven countries in Europe, latterly handling employee relations in Europe, Middle East and Africa. Fiona joined Roche in 2006 where she was most recently responsible for global human resources for Pharma Technical Operations. Her primary focus was to identify and develop a sustainable supply of leadership and talent from within the organisa-tion. Before this, Fiona was HR and Communications Director for Roche Italy where she was responsible for HR, Corporate and Product Communications, patient advocacy and public affairs. Fiona’s initial focus on join-ing AstraZeneca is to provide continued support for the transformation of the organisation and culture to achieve the strategic priority of being a Great Place to Work.

Fiona CicconiExecutive Vice President,Human ResourcesAstraZeneca


34

Richard has worked in life science recruitment for the past 14 years. Currently the Operations Director for SRG,

Richard focuses on the recruitment of science profes-sionals across the UK and Europe. Having graduated in Microbiology and Genetics from Leeds University,

Richard worked as a Forensic Scientist for FSS in London in the crime scene DNA Laboratories. After 4 years,

Richard moved into a role which allowed him to utilise both scientific knowledge and commercial acumen and

joined SRG as a recruitment consultant. Having held various senior level positions within the company across both science and engineering, Richard now heads up the

Executive level recruitment business. SRG is an award-winning resourcing company dedicated to the science,

clinical and engineering sectors. Delivering a broad range of contract and permanent opportunities for graduate to

senior management level. SRG’s clients range from the world’s top five pharmaceutical companies through to spin

out technology firms.

Richard ActonOperations Director

SRG

Brindan Suresh is a partner in McKinsey’s London Office, specialising in healthcare. Brindan studied and obtained a BA (Govt), LLB (HonsI) and an MD from the Univer-sity of Sydney - his key areas of expertise now lie within

Healthcare Systems and Services, Pharmaceutical ‘Go to Market Models’, Medical Affairs and Strategy and or-

ganization design. Brindan has recently been working on several projects including: working with NHS leaders in

London on large scale integrated care provision involving 2m+ patients, supporting the launch of new products for

a number of pharmacos and their commercial business units, re-designing the strategy, structure and opera-

tions for a number of global and regional R&D/Medical Affairs organisations across a range of pharmacos and

working with a major pharmaco to establish the role of digital channels in boosting overall productivity/process

efficiency and customer engagement.

Dr Brindan SureshPartner

McKinsey & Company

Peop

le G

ap


35

Lead

ers

of T

omor

row

Fie

ld T

rip

Charlotte Whicher studied her undergraduate degree (BA (Hons)) in Physiological sciences at the University of Ox-ford. From there she moved to Zurich, Switzerland, where she worked as a research assistant on amyloidosis in Adri-ano Aguzzi’s lab in the University Hospital Neuropathol-ogy Department. She then returned to the UK and joined the Division of Immunoregulation at the MRC Francis Crick Institute, Mill Hill laboratory (formerly the MRC National Institute for Medical Research) to complete her Infection & Immunology PhD in Anne O’Garra’s lab. Here she specialised in transcriptomics and the regula-tion of immuno-modulatory protein gene expression. She is now Product Manager for Repositive, helping build a software platform to facilitate efficient and secure data access, data sharing and data collaborations for genomics research. She takes a keen interest in the issues surround-ing finding and accessing human genomics data and is an advocate of the Open Science movement.

Dr Charlotte WhicherProduct ManagerRepositive

Dr Allen Eaves, MD PhD FRCPC, has been Found-ing Director of the Terry Fox Laboratory (1981-2006), Head of Hematology at UBC (1985-2003), President of the International Society of Cell Therapy (1995-1997), President of the American Society of Blood and Marrow Transplantation (1999-2000), and Founding Treasurer of the Foundation for the Accreditation of Cellular Thera-pies (1995-2002). As Professor Emeritus of Hematology at UBC (2006-present), he is owner and CEO of STEM-CELL Technologies Inc., Canada’s largest biotechnology company with over 800 employees. A supporter of Cana-da’s Networks of Centres of Excellence, he has been chair of the board of MITACS and is currently on the boards of The Canadian Stem Cell Network, The Canadian Centre for Regenerative Medicine, and The Canadian Foundation for Stem Cell Research. He is passionate about creating jobs in industry for smart young people who love science.

Dr Allen EavesCEOSTEMCELL Technologies

Graham has a Master Degree in Biophysics, an MBA and holds a professional financial qualification, gained when working for Deloitte LLP. He has been CEO of Immu-noBiology Ltd since 2006. Prior to that, he has worked in senior positions within healthcare and life sciences, including as VP, Strategy & Business Development, GE Healthcare Life Sciences; Head of R&D Executive Support, GSK; and VP, Strategic Product Development, SmithKline Beecham. Graham is also a board director of NHS Health Research Authority and a governing member of the Institute of Cancer Research.

Graham ClarkeCEOImmBio 35


36

Dr Marcus Yeo is a founder and CEO of DefiniGEN. He is an experienced Company Director and life scientist who took the Oxford-based diagnostics biotechnology com-

pany Cybersense Biosystems Ltd to acquisition in 2008 by the FTSE 100 company Severn Trent. He oversaw the in-

tegration of the business into the Severn Trent ISO 17025 structure and led sales and marketing of the Severn Trent analytics division. Marcus also has previously worked for the University of Oxford company Zyoxel Ltd. (now CN

Bio Innovations), which markets advanced 3D human tissue culture systems to the investigative toxicology drug

discovery sector. He specialised in the development of next-generation stem cell derived liver toxicology products

and disease modelling systems for drug discovery lead optimisation. He has a PhD in Molecular Biology and is an accredited European Commission Technology Expert who

has managed in excess of £15m of R&D funding.

Dr Markus YeoCEO

DefiniGEN

Crowd (marketplace) finance is re-writing the way those with funds and those requiring funding meet. It is a mul-ti-billion dollar, global unbundling of traditional funding systems. Thousands of platforms exist creating a complex

new industry, with huge social implications for billions worldwide. An informed reaction to this huge change requires adequate data intelligence, so Emily founded Crowdsurfer. Their data intelligence enables users to

search and act using Crowdsurfer’s dashboard and API.

Emily MacKayCEO

Crowdsurfer

Marianne Brüggemann obtained her PhD in Natural Sci-ences from the University of Cologne, Germany, working

on antibody diversification in Prof. K. Rajewsky’s laborato-ry. Her postdoctoral work at the University of Cambridge in Prof. H. Waldmann’s laboratory identified the layout of

the rat immunoglobulin heavy-chain (IgH) locus, which provided an important contribution to early engineering of ‘humanized’ rodent antibodies. At that time the need for fully human therapeutic antibodies was realized and

she assembled a germline configured human IgH con-struct, which, in collaboration with M. Neuberger, MRC,

and A. Surani, Babraham, generated the first transgenic mice expressing human antibody repertoires. Patented

work continued on human antibody expression, knock-out technology, artificial chromosomes and transgenic

animals expressing single-chain antibody repertoires. Her academic research at the Babraham Institute was followed in 2010 by becoming Research Director of RAT, where she

established transgenic opportunities including domain antibody repertoires; the smallest antigen-binders.

Dr Marianne BrüggemannCEO

Recombinant AntibodyTechnology

Lead

ers

of T

omor

row

Fie

ld T

rip

36


37

Lead

ers

of T

omor

row

Fie

ld T

rip

Nadia joined One Nucleus just over a year ago after her Postdoctoral Fellowship at the University of Cambridge. Since her PhD at the Babraham Institute, she has worked in both academia and industry as a Cellular and Molecu-lar Biologist, in companies such as Domainex and Med-Immune. Nadia is currently the Events & Business Devel-opment Manager at One Nucleus. In her role she leads on ON Helix, their annual translational medicine conference held in Cambridge, organises and runs network meet-ings both in Cambridge and London but also works with members to become more globally competitive.

Dr Nadia ShivjiEvents & BusinessDevelopment ManagerOne Nucleus

Nadine Su has nearly 20 years international business development and project management experience in UK and China in the technology and healthcare industry. In China, she successfully developed new clients for one of the largest bank groups in China. In UK, she success-fully managed an American blue-chip company for a UK healthcare company to increase their sales. She is the founder of Cambridge-based technology brokerage company – MedTech International Ltd to work with the team to help several UK and European small novel drug discovery research companies to successfully license their technology to Chinese companies or attract investment to the company and move their research projects forward to clinical stage.

Nadine SuMarketing DirectorMedTech International

David Gill is Managing Director of the St John’s Innova-tion Centre in Cambridge. He previously set up and ran the Innovation & Technology Unit at HSBC Bank in Lon-don (1997-2004), then served as an executive director of a venture fund focused on early-stage, technology-based investments (2005-08). Educated at Cambridge, he was called to the Bar by the Middle Temple before working in corporate finance for US and UK banks. A Sloan Fellow at the Stanford Graduate School of Business in California (2004-05), David is currently an Academic Collaborator at the University of Cambridge Institute for Manufactur-ing and non-executive director of a number of start-up companies (Psonar Ltd, Syndicate Room Ltd). He is also a non-executive director of the Greater Cambridge Greater Peterborough Enterprise Partnership, and chair of the steering committee of ideaSpace, the University of Cambridge pre-incubator. David is the co-author of numerous publications on innovation, incubation and finance.

David GillManaging DirectorSt John’s Innovation Centre


38

Lead

ers

of T

omor

row

Fie

ld T

rip

Dr Wei Li is a British Heart Foundation Lecturer in Vascular Biology, based at the Department of Medicine, University of Cambridge. She obtained her PhD at University of East An-glia under the supervision of Prof. Colin Kleanthous and in the field of kinetics and thermodynamics of protein-protein

interaction and protein engineering. She subsequently did postdocs with Prof. Jim Huntington in the field of protein

biochemistry and protein crystallography, characterized human proteins including full-length huntingtin and serpin

family protease inhibitors. She became a BHF lecturer in 2010 and started working on the mechanisms of bone

morphogenetic protein regulation, using a range of ap-proaches including biochemistry, protein engineering,

crystallography as well as cell signalling and functional assays. Together with Prof. Nick Morrell and Dr Paul

Upton, she is a co-founder of MORPHOGEN-IX, a spin-off company to develop bone morphogenetic proteins as

a novel therapy for the treatment of pulmonary arterial hypertension.

Dr Wei LiCo-Founder

MORPHOGEN-IX

Dr Mander has over 24 years of small molecule drug discovery and translational research experience in both

scientific and commercial roles. He completed his DPhil at the University of Oxford before undertaking scientific positions with the natural product company Xenova and

with the Centre for Natural Product Research in Singa-pore. In 1995, Tom joined Glaxo Wellcome as group leader

for cell-based HTS, working with therapeutic groups across Glaxo Wellcome sites and helping to discover a

number of starting points for lead optimization. As well as his scientific experience, Tom has also held multi-

ple management positions, including Vice President of Business Development at EVOTEC Biosystems. He has

also been on the management teams of Tripos Discovery research and Asterand, and most recently before joining

Domainex, took up a business development assignment at Biofocus (now part of Charles River Laboratories). Tom

joined Domainex in April 2015 and has responsibility for operational and commercial activities for the service busi-

ness of the company. He has developed relationships with organisations in the UK, Europe, North America and Japan to provide high quality and tailored solutions to support their drug

discovery and diagnostic projects.

Dr Thomas ManderCOO

Domainex


39

Lea

ders

of T

omor

row

Fie

ld T

rip

Dr Chibeza Agley is a Research Fellow at the University of Cambridge and founded CamBioScience Limited in 2014 with the initial aim of helping scientists to develop their commercial awareness. Working with the Cam-BioScience Directorship, Dr Agley grew the company from its origins as an interdisciplinary academic-to-industry consultancy service, to an international business supporting Biotech, Pharma and Healthcare industries worldwide. His current interdisciplinary research at the University of Cambridge Stem Cell Institute amalgamates the fields of stem cell biology, physics and bioengineer-ing. Chibeza continues to publish scientific papers and has received a number of notable academic awards for his research including the ‘Tadien Rideal Prize for Molecular Science’ in recognition of his PhD thesis. He maintains excellent local links with the Cambridge Biotech Cluster and the UK advertising industry and has developed many long-standing global partnerships. As Chief Executive Officer of CamBioScience, Chibeza is focused on deliver-ing innovative solutions to support the market penetration and expansion of new and existing Life Science associated brands.

Dr Chibeza AgleyCEOCamBioScience

Sarah started her career in the NHS and is a graduate of the NHS Management Training Scheme in Wales. Sarah worked in a number of NHS Trusts, latterly Great Ormond Street NHS Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit, located on the UCL campus. From there Sarah joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BIS) Bio-science Unit before it became part of the Office for Life Sciences. Sarah’s last role in BIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. Sa-rah joined London & Partners in January, 2014 and dur-ing this time has worked with Dr Eliot Forster, Executive Chair of MedCity, to establish the company and organisa-tion. Sarah has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Management Charter Institute.

Sarah HaywoodCEOMedCity


40

Bioe

thic

s G

apSilvia Camporesi is a bioethicist trained in biotechnology

in Italy and the US and philosophy of medicine in the UK. She is currently based in the Department of Social Science,

Health & Medicine at King’s College London where she is programme leader for the MA in Bioethics & Society. She was

formerly at the Department of Anthropology, History and Social Medicine at UCSF. Silvia works on the ethics of emerg-

ing biotechnologies; in particular she is interested in how genetic technologies shape new ways of life and on the ethical implications. Her book “From Bench to bedside to track and

field: the context of enhancement and its ethical relevance” was published for UC medical Humanities Press in 2014. She

has coauthored a new book coming out later in 2016 titled “Bioethics Genetics and Sport”.

Dr Silvia CamporesiLecturer in

Bioethics & SocietyKing’s College London

Tim's undergraduate training was at the Universities of Cambridge and London, followed by postgraduate train-

ing in Oxford and Montreal (McGill University). Following completion of RCOG Sub-Specialist Training in Reproduc-tive Medicine he was appointed in 2004 as a Senior Fellow

in the NDOG and an Honorary Consultant Gynaecologist at the John Radcliffe Hospital. He is currently Medical Director

of Oxford Fertility and a Founding Director of The Fertility Partnership, the UK’s largest assisted conception network.

Tim was appointed as an Associate Professor in the NDOG in 2015. Tim is a member of the Guidelines Development Group for Fertility for NICE (National Institute for Clini-

cal Excellence), on the board of the fertility lobbying group Fertility Fairness, and a member of the Teaching Board for

the University of Oxford MSc in Clinical Embryology.

Mr Tim ChildMedical Director

Oxford Fertility

Dr Lucivero is currently employed as Marie Curie Fellow at the Social Science Health and Medicine department at King’s College London, where she conducts research on the ethical

social and political aspects of technological innovation in the biomedical field. She has written on a number of biotechnolo-gies (brain-computer interfaces, molecular diagnostics, robots

and e-healthcare) and her expertise spans across different areas and disciplines: ethics and social studies of science and technology, governance of innovation, philosophy of science and technology, and empirical bioethics. In her research, she

combines theoretical and methodological questions with empirical investigation. Her current project investigates the ethical challenges of digital technologies in healthcare, spe-

cifically looking at mobile apps and personal health records. Currently, she serves as KCL representative in the Working

Group on mHealth guidelines at the European Commission.

Dr Federica Lucivero Marie Curie Fellow

King's College London

40


41

Bioe

thic

s G

ap

Lenias Hwenda is an interdisciplinary professional, a scientist and a global health policy expert who works on improving access to medicines in African countries and other emerging markets. Her policy-making work in the multilateral environment has involved high-level policy negotiations on various critical issues of global concern such as the impact of intellectual property rights and global trade rules on patient access to treatment. Lenias has worked as part of the African negotiating team involved in shaping the global response to pandemic influenza preparedness, counterfeited medicines, health workforce challenges, and the prevention and control of non-communicable diseases. Lenias was trained as an immunologist, and prior to her work in global health policy, she worked on infectious diseases developing vac-cines for influenza and malaria and microbicides for HIV at the University of Oxford and Rockefeller University.

Dr Lenias HwendaFounderMedicines for Africa

John Harris FMedSci., Member, Academia Europaea., FRSA., B.A., D.Phil., Hon. D.Litt. is Emeritus Professor of Bioethics, University of Manchester. His books In-clude: The Value of Life, Routledge 1985, Wonderwoman and Superman, Oxford University Press 1992, Clones Genes and Immortality, Oxford University Press, 1998. John Harris Ed. Bioethics. Oxford Readings in Philoso-phy Series, Oxford University Press. 2001, Justine C. Burley and John Harris Eds. A Companion To Genethics: philosophy and the genetic revolution. Basil Blackwell, Oxford. 2002, (Blackwell’s Companions to Philosophy series), On Cloning, Routledge. London, 2004, Enhanc-ing Evolution was published by Princeton University Press in 2007.

Tim is the Principal Investigator for the ERC-funded project "A Science of Human Nature? "(2011–2016). From 2009 to 2015 he was a Council Member of the Nuf-field Council on Bioethics, and served on the working parties for two Nuffield Council reports: Novel Tech-niques for the Prevention of Mitochondrial DNA Disor-ders: An Ethical Review (June 2012), and Human Bodies: Donation for Medicine and Research (October 2011). He is also the Deputy Director of CRASSH, the Centre for Research in Arts, Social Sciences and Humanities.

Prof. Tim LewensProfessor of Philosophy of ScienceUniversity of Cambridge

Prof. John HarrisLord David AllianceProfessor of BioethicsUniversity of Manchester


42

Publ

ic P

erce

ptio

n an

d Ed

ucat

ion

Gap

Lisa Melton runs the news section for Nature Bio-technology, a scientific journal that focuses on all sectors of biotechnology: biomedical, agricultural and industrial. Lisa earned a degree in Biochem-istry and a PhD in Immunology in Buenos Aires,

Argentina. As a science writer, her pieces have been published in the Economist, the Times, and New Sci-entist among others. She is also a lecturer at the MSc

in Science Communication at the University of the West of England. Lisa joined the Nature Publishing

Group in 2008.

Lisa MeltonSenior News Editor

Nature Biotechnology

Tim is a serial Tech & Social entrepreneur in rare diseases. He is the Founder & CEO of Healx and

Co-Founder & Chair of the charity Cambridge Rare Disease Network (CRDN). His number one passion

is applying big data analytics to help rare disease patients in need. In 2015, Healx was awarded “Life

Science Business of the Year” at the Grand Finale of Cambridge University Entrepreneurs and raised

seed investment from the ‘Blue Chip’ investors of the Cambridge Cluster. Both CRDN and Healx were covered by the BBC, Radio 4 and The Independent.

Prior to Healx and CRDN, he worked on Univer-sity-Industry interactions for the UK Gov (BIS). He obtained his PhD in the field of Biophysical

Neuroscience at the University of Cambridge, where his research related to Parkinson’s disease. Before moving to Cambridge, Tim obtained an MEng in Bio-Engineering from the University of Brussels.

Tim GuilliamsCEO

Healx


43

Simon BurallDirectorInvolve

Simon Burall is the Director of Involve. He has long and extensive experience in the fields of democratic reform, governance, public participation, stakeholder engagement, and accountability and transparency. He has worked at the national level in Africa, Asia and Europe as well as on related issues of global governance and democracy. In addition to his role with Involve, Simon is also Head of Dialogue at the ScienceWise Expert Resource Centre and a Fellow WWF UK. He has recently finished his term as Chair of Democratic Audit. Before moving to Involve Simon was a Research Fellow at ODI from 2006 – 2009. His interests included stakeholder engagement in the reform of the interna-tional aid delivery system and how to make develop-ment finance more effective. Prior to this he was the Executive Director of the One World Trust from 1999 – 2005 where he initiated and oversaw the develop-ment of the influential Global Accountability Index. Simon has taught both science and English in Namibia and Zimbabwe and was an election monitor in Bosnia Herzegovina after the Dayton Agreement.

Since October 2014, Anna has been Communities Manager at the British Science Association, coordinat-ing their work with science communicators and science policy, and running schemes like the Media Fellowships. She is secretary of Stempra (STEM Public Relations Association) and has previously worked in media and policy roles at the open access publisher, BioMed Cen-tral, the Association of Medical Research Charities and Understanding Animal Research. In her freelance work, she has done a mix of writing, event curation and project management work for organisations like the Guardian, UCL, TEDxAlbertopolis at the Royal Albert Hall and Design Science. Anna has a Masters in Science Com-munication from Imperial College London, and is a Fellow of the RSA.

Publ

ic P

erce

ptio

n an

d Ed

ucat

ion

Gap

Anna PermanCommunities ManagerBritish Science Association


44

Voic

es o

f Tom

orro

wVoices of Tomorrow

Global Bio-innovation Competition Finals

The Voices of Tomorrow competition is designed to provide a platform for inspiring and supporting Leaders of Tomorrow in biotechnology worldwide to develop breakthrough solutions to challenges in the global bioeconomy.

Teams were formed from 100 selectedLeaders of Tomorrow to develop ideas forinnovative projects to practically solve a problem identified. Guided by mentors, eachteam submitted an initial project proposal,and the ten best teams were chosen as finalists topitch their ideas to a panel of expert judgesduring the GapSummit 2016.

Following the pitches, the top three teams will be commended by the judges and awarded prizes, which will include additional mentorship opportunities from Roche to help them fur-ther develop and implement their project proposals. An additional £2,000 will be awarded to the first placed team to further support their proposal.


45


Fina

list S

elec

tion

Pan

el

Miranda helps early stage biomedical businesses attract investment and develop their business strategy. She founded and runs BioBeat, a programme to inspire the next wave of bioentrepreneurs and business leaders. Miranda has worked with many entrepreneurs and is experienced in fundraising, business planning and technology transfer. She is a long standing Mentor for Cambridge Judge Business School’s Entrepreneur-ship Centre, contributes to the University of Cam-bridge Masters in Bioscience Enterprise course and is a member of the St John’s Innovation Centre Training Team. She brings experience as a Technology Manager at Cambridge Enterprise, where she assessed and mar-keted life science technologies, negotiated licences and spun-out companies. She was responsible for technol-ogy transfer at the University of Cambridge for the Cam-bridge-MIT Institute. In her five years at the seed capital firm, Cambridge Research and Innovation, she invested in early stage technologies. Miranda studied Natural Sciences at the University of Cambridge and has a Diploma from the Chartered Institute of Management Accountants.

Miranda Weston-Smith

Professor Alan Barrell, DBA., FRSA is Entrepreneur in Residence at the Centre for Entrepreneurial Learning, Judge Business School, University of Cambridge. He has spent some 30 years in senior executive positions in technology-based industries and has become one of Cambridge’s most articulate promoters of entrepre-neurship around the world. He has received a large number of honorary positions and is a lecturer in high demand at universities all over the world. Alan has been in invited to Lahti University of Applied Science as the first Honorary Research Fellow of the University.

Prof. Alan BarrellEntrepeneur in ResidenceJudge Business School,University of Cambridge


46

Judg

esDr Judith Dunn is a member of Roche’s pharma Research

and Early Development (pRED) Leadership Team, focused on the discovery and early development of new

medications that significantly improve the lives of pa-tients and their families. As Vice President of Clinical De-velopment, Judy leads several functions which contribute

to the design and execution of clinical programs across all therapeutic areas in the pRED portfolio (Immunology

and Inflammation, Infectious Diseases, Neuroscience, Oncology, Ophthalmology, and Rare Diseases) from

Entry into Human to Proof of Concept. Additionally, Judy is the head of the Roche Innovation Center, NYC.

Judy has more than 25 years of international experience in the pharmaceutical industry. She began her career as

a discovery scientist in biotech, held positions in both the research and Commercial divisions of Pfizer, and

led Psychiatry Clinical Development efforts at Sepracor, a specialty pharma company. Judy attended Wesleyan University and the University of Rochester, obtaining

undergraduate and graduate degrees in Neurobiology. She was the recipient of a Research Fellowship in Neuropharmacology from the Center for

Brain Research at Strong Memorial Hospital, as well as a Postdoctoral Fellowship in Clinical Research from Pfizer. Judy is an active member of the NYC life sciences community where she works to promote collaboration and growth. Judy is a board member of NewYorkBIO

and the Partnership for New York City.

Dr Judith DunnVice President,Global Head of

Clinical DevelopmentRoche Innovation Center

Mark Goodson is currently Lead Business Advisor at Social Incubator East and a Consultant Venture Manager

for UnLtd. Since July 2014 Social Incubator East has incubated 60 ventures including a number of growing

biotech startups. Social Incubator East recently became part of the Centre for Social Innovation at Cambridge

Judge Business School. Mark has worked for over 30 years in technology including co-founding venture

capital funded startups and senior positions at companies such as Cambridge Silicon Radio.

Mark GoodsonLead Business Advisor

Social Incubator East


47

Matthias is a Director in McKinsey’s Hamburg office and co-leader of the Global Pharmaceuticals and Medi-cal Products R&D and Medical Practice. Since joining the firm in 2002, Matthias has engaged with pharma-ceuticals and biotech clients in Europe, the U.S. and Asia on transforming R&D/Medical to overcome inno-vation and productivity issues. He also drives a number of cross-industry/acadmia partnership projects with an eye on strengthening leadership in sciene and medi-cine. Matthias holds a Ph.D. in Biochemistry from the University of Bochum. Before his career with McKinsey, he worked as a Research Associate and Postdoctorate at a Center for Molecular Neurobiology in Hamburg. He has authored several articles in the fields of bioinfor-matics and molecular biology.

Cathy has over 23 years of experience in research, man-agement and business in the biotechnology, pharma-ceutical and venture capital sectors. She is currently the director of the consultancy Biolatris Ltd; non-executive director to Videregen Ltd; advisory board member of Trakcel Ltd and a Member of the Board of Trustees IMET2000. Cathy also founded the ‘Quartet’, a consor-tium of senior representatives of the reinsurance and pensions advisory services researching the potential impact of emerging technologies on the financial services sector. Cathy is a mentor to the Ignite Summer Business School programme (Centre for Entrepreneurial Learning, Cambridge University), a Senior Associate for the Masters in Bioscience Enterprise (Cambridge University) and Visiting Professor at Kings College, Lon-don. She is a co-editor and contributor to ‘The Delivery of Regenerative Medicines and Impact on Healthcare’

Judg

es

Dr Cathy PrescottFounder DirectorBiolatris

Dr Matthias EversDirectorMcKinsey & Company


48

Judg

es a

nd M

ento

rsRobert joined Cambridge Innovation Capital in January 2014 as Investment Director with a focus on life sciences

and associated technologies. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clinical

team for the regulatory approval of Valcyte®. Twelve years ago, Robert joined the Cambridge based company Arakis

and worked as Medical Director until its £106m sale to Sosei Inc. Since that acquisition, Robert has been involved in a number of start-up companies including founding the

malaria-focused company Treague, being founding CEO of the University of Copenhagen spin-out Avilex Pharma and

being part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School. Robert quali-fied in medicine from University College London, he is a member of the Royal College of Obstetricians & Gynae-

cologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in

Biostatistics from the University of Cambridge.

Dr Robert TansleyInvestment Director,

HealthcareCambridge Innovation

Capital

Voices of Tomorrow MentorsDr Felicia Pagliuca, VP Technology & Corporate Development, Semma TherapeuticsDr Kamal Jit Singh, Representative, Private Investor GroupDr Kelvin Chan, Scientist-entrepreneur & Research Fellow, A*STARDr Sheng-hong Chen, Ruth L. Kirschstein Research Fellow, Harvard Medical SchoolMuntaqa Umar-Sadiq, CEO, Private Sector Health AllianceDr David Hampton, Senior Associate, Biotechnology Institute,University of CambridgeStewart McTavish, Director of ideaSpace, University of CambridgeMatthew Scholz, CEO, ImmusoftAdina Mangubat, CEO, Spiral GeneticsMainda Kiwelu, Strategist & Founder, ADNIAM HouseDr Chibeza Agley, Founder & CEO, CamBioScienceDr Shamus Husheer, Heartfelt Technologies LtdUrvashi Prasad, Director, Operartion ASHA


49

Men

tors

Dr Pagliuca is a co-founder of Semma and currently serves as Vice President of Technology and Corporate Development. She leads internal cell biology research and development and plays a key role in Semma’s pre-clinical, regulatory, and manufacturing strategies for cell therapy products. Dr Pagliuca also works closely with Semma’s senior leadership on corporate development, including key collaborations and partnerships. Previ-ously, she worked with Professor Doug Melton at the Harvard Stem Cell Institute on the discovery of how to generate stem cell derived beta cells. She is an expert in stem cell biology and diabetes and an inventor of Semma’s key technologies. She received a B.S. from Duke University and a Ph.D. from Cambridge Univer-sity where she was a Marshall Scholar.

Dr Felicia PagliucaVP Technology &Corporate DevelopmentSemma Therapeutics

Dr Kamal Jit Singh represents a private group of inves-tors who acquire and build companies grounded in Intel-lectual Property. He was previously the founder CEO of Malaysia’s Innovation Agency and the Malaysian Special Innovation Unit, Executive Director of the Global In-novation Research Centre and CEO of BT Malaysia’s Asian Research Centre. He is also the author of Malay-sia’s National Innovation Strategy and set up the first Design Thinking school (in collaboration with Stanford University’s School) in the ASEAN region. More than 400 SMEs use his “Science of Innovation” methodology, a structured process for designing products and services with a demonstrable competitive edge. Kamal has a Doctorate in Strategic Management and an MBA from Southern Cross University, Australia. He also holds an MPhil from University of Cambridge in Bioscience En-terprise. Kamal’s interest is in identifying and applying disruptive technologies that cross industry boundaries, creating a sustainable competitive advantage.

Dr Kamal Jit SinghRepresentativePrivate Investor Group


50

Men

tors

Dr Kelvin Chan has a Ph.D. in Organic Chemistry from The Scripps Research Institute, USA, and a B.A. (Honors) in Chemistry from the University of Cambridge, UK. Dr Chan was a founder of several chapters of the Oxbridge

Biotech Roundtable, a global life science organization that connects academia with industry. He has hands-on ex-

perience in startups, business strategy, and management, with an emphasis on venture capital. Dr Chan is advisor to PureWick, a Class I medical device company focused on the management of female incontinence. Dr Chan is a fellow of the Agency for Science, Technology and Re-

search (A*STAR), Singapore’s lead government agency for fostering world-class scientific research and talent, where

he is currently researching radiochemistry strategies for PET applications. He is also a concertizing pianist.

Dr Kelvin ChanResearch Fellow

A*STAR

Sheng is the founding president of the Boston Taiwanese Biotechnology Association. BTBA is a non-profit organi-

zation aiming to enhance scientific collaborations, to foster individual career development, to facilitate inter-actions and to strengthen networking among academic

and industrial bioscience communities in Taiwan and the U.S. Sheng is trained as a multidisciplinary scientist working at the interface of biology and quantitative sci-

ences. He received a Master degree from University of Sussex in Artificial Life and Artificial Intelligence, and a Ph.D. degree from University of California San Diego in Biological Sciences. He is currently a Ruth L. Kirschstein

Research Fellow in Harvard Medical School, investigat-ing cellular control using single-cell signaling dynamics with an emphasis on cancer therapeutics. Sheng is espe-

cially passionate about promoting innovative scientific research by bridging academia and industry and has

been involved in multiple collaborative projects between academic laboratories and industry (Merck and Novartis

Institutes for Biomedical Research).

Sheng-hong ChenRuth L. Kirschstein

Research FellowHarvard Medical School


51

Dr David Hampton is a research scientist and entrepre-neur focused on bringing medical innovations to inter-national markets. He is the founder of CamStent Ltd (UK), developing bacteriaphobic coatings that prevent hospital-acquired infections, and Acacia Designs BV (NL), creating surgical monitors in collaboration with the Mayo Clinic. His consultancy, Stone Bridge Bio-medical BV (with locations in Seattle, Cambridge and Maastricht) fosters medtech innovation and global en-trepreneurship for clients by shepherding their creative, often game-changing, ideas into successful products. Holding more than 25 patents, Dave was a Research Di-rector and elected Fellow at Medtronic and is a Senior Associate teaching in the Biotechnology Institute at the University of Cambridge. His academic background includes an MPhil from Cambridge, Management Sci-ence study at Stanford University, and a doctorate in Biomedical Engineering from Northwestern University.

Dr David HamptonSenior AssociateBiotechnology Institute,University of Cambridge

Muntaqa Umar-Sadiq is the Chief Executive Officer and founding board member of the Private Sector Health Alliance (PHN) – the foremost private sector coalition focusing on mobilizing private sector resources, capa-bilities, innovation and partnerships to complement government’s efforts in advancing health outcomes in Nigeria. Muntaqa was the Senior Technical Advisor to the former Honourable Minister of State for Health in Nigeria, Dr Muhammad Ali Pate. In this position, he was responsible for leading a number of landmark healthcare reform programs. He commenced his career as a healthcare investment banker at Morgan Stanley in the UK where he focused on the Healthcare & Pharma-ceutical sector. Umar-Sadiq is a graduate from the Uni-versity of Cambridge, England, where he did an M.Phil in Bioscience Enterprise and undertook an MBBS / Medical sciences degree at Imperial College School of Medicine, London. He is also a Chartered Alternatives Investment Analyst (CAIAI) charter holder.

Muntaqa Umar-SadiqCEOPrivate SectorHealthAlliance

Men

tors


52

Stewart McTavish is the founding Director of the University of Cambridge ideaSpace, which was created as a community

space for early stage innovators and entrepreneurs. The com-pany’s focus has grown to include using policy to support innovation, enterprise and entrepreneurship. Prior to his

current role, Stewart founded an open innovation platform company managing startups processes for corporate clients. His current research interests include cluster theory, startup

models, co-working and community spaces, innovation management and funding for high growth ventures.

Stewart McTavishDirector of ideaSpace


Men

tors


2016GapSummit 53


Lead

ers

of T

omor

row

Abdulrahman Idoko Adam Master's Student, University of Glasgow [email protected]

Adedapo Adediji PhD Candidate, University of Ibadan/IITA, Nigeria [email protected]

Adriana R. Kyvik Pre-doctoral Researcher, Icmab-Nanomol [email protected]

Ainnatul Adawiyah Ahmad Termizi Founder, Rephytomed

ainnatul.ahmadtermizi @uqconnect.edu.au

Aisyah Noor PhD Bioinformatics, King's College London [email protected]

Dr Alberto Loche COO,

European Institute for Translational Medicine

[email protected]

Alexey Tomsov Entrepreneur, MSc Student at The Technion [email protected]

Alice Nettleton IP Management Intern, IP Pragmatics [email protected]

Dr Andreas Hougaard Laustsen Founder, VenomAb IVS [email protected]

Dr Angela Lim CEO, Catalyst Point [email protected]

Anjui Wu PhD Candidate, Institute of Cancer Research [email protected]

Anne Loechner PhD Candidate, MPI Marburg & Synmikro

[email protected]

Ari Cuperfain Medical Student, University of Toronto [email protected]

Ari Dwijayanti PhD Candidate, Imperial College London [email protected]

Aude Richter Global Alliance and

Asset Management Director, Roche

[email protected]

Ayan A. Abukar Co-Founder, Acorn Cryotech [email protected]

Carlos Villacís Biotechnology Professional, Bayer HealthCare [email protected]

Charalampia (Chara) Koutsioumpa Medical Student, University of Ioannina, Greece [email protected]

Charles Jourdan F. Reyes Master's Student, Osaka University [email protected]

Chiara Prodani Graduate Scientist, AstraZeneca [email protected]


54

Lead

ers

of T

omor

row

Christoffer Johnsson Industrial Graduate Student, Stora Enso/SLU [email protected]

Conor McGlynn MPhil Philosophy, University of Cambridge [email protected]

Cristian Riccio PhD Candidate, University of Cambridge [email protected]

Daniel Bode BSc Student, University of Dundee [email protected]

Daniel Molina Romero Researcher,

Instituto Tecnologico y de Estudios Superiores de Monterrey

[email protected]

David Booth Fundraising Operations and Growth, AngelList [email protected]

Dominik Sievert Founder and CEO, PIVET - Scientific Solutions [email protected]

Emil Syundyukov Master's Student, University of Latvia [email protected]

Eric Felli Trainee, King's College London [email protected]

Felix Breyer Undergraduate, University of Dundee [email protected]

Dr Filipa Soares Product Development Manager, Definigen [email protected]

Dr Fulvio Zaccagna Clinical Research Fellow, University of Cambridge [email protected]

Gavin Poon MPhil Student, University of Cambridge [email protected]

Glen Gowers Master's Student, Oxford University [email protected]

Hanae Shimo PhD Candidate, University of Cambridge [email protected]

Harsheel Singh Soin Undergraduate,

Indian Institute of Technology Kharagpur

[email protected]

Helena Andres Terre PhD Candidate, University of Cambridge [email protected]

Hsiao-Lan (Donna) Pu MBA Candidate, Duke University [email protected]

Humaira Noor PhD Candidate, University of Sydney [email protected]

Ian Dardani Master's Student in

Bioscience Enterprise, University of Cambridge

[email protected]


2016GapSummit 55

Lead

ers

of T

omor

row

Jan G Botthof PhD Candidate, University of Cambridge [email protected]

Jason Kerr Master's of Bioscience, Keck Graduate Institute [email protected]

Jeffrey Teoh PhD Candidate, University of Virginia [email protected]

John Hon Master's Student, University of Cambridge [email protected]

Jonas Schmid PhD Candidate, University of Zurich [email protected]

JD Santillana-Ortiz PhD Candidate, University of Düsseldorf, Germany [email protected]

Julius Bruch Associate, McKinsey & Company [email protected]

Kaisar Dauyey Master's Student, Nazarbayev University [email protected]

Kaushala Ratnayake COO, Chiasma [email protected]

Kenneth Lui Master's Student, University of Cambridge [email protected]

Khady Nani Dramé Molecular Biologist, AfricaRice [email protected]

Kristýna Schinnenburgová MPhil Bioscience Enterprise, University of Cambridge [email protected]

Leonardo Nunes CEO, Novalact [email protected]

Lotte van Beek PhD Candidate, Eindhoven University of Technology [email protected]

Luis García Manríquez Master´s Student, Imperial College London [email protected]

Lukman Aroworamimo Managing Director, Inqaba Biotec West Africa

lukan.aroworamimo @inqababiotec.ng

Marcelinus Rocky Hatorangan Research Director, CV Augenetics Indonesia [email protected]

Marcus Paulsson Procurement Manager, AstraZeneca [email protected]

Maria Oh PhD Candidate, UNSW, Australia [email protected]

Marie Yurkovich PhD Candidate in Biochemistry, University of Cambridge [email protected]


56

Lead

ers

of T

omor

row

Dr Marina Carla Cabrera Postdoc, MedImmune/AstraZeneca

[email protected]

Dr Massimiliano Clamer CEO, Immagina BioTechnology [email protected]

Matthew Liebers Senior Analyst, Fletcher Spaght [email protected]

Max Mundt PhD Candidate, Center for Synthetic Microbiology MPI

[email protected]

Michelle Teplensky PhD Candidate, University of Cambridge [email protected]

Miha Pipan CSO, Entomics [email protected]

Mo Awwanah Master's Student, Leiden University [email protected]

Nadine Bongaerts Founder, Biotecture [email protected]

Nicolas Koutsoubelis PhD Candidate, MPI Marburg & SYNMIKRO

[email protected]

Nishit Srivastava PhD Candidate, University of Cambridge [email protected]

Ojas Mehta Physician Trainee, Royal Melbourne Hospital [email protected]

Osric Forrest PhD Candidate, Emory University [email protected]

Patty Tsai CRA, Novartis (Taiwan) [email protected]

Pei-Chen Chu CRA, PAREXEL [email protected]

Petar Todorov Graduate Scientist, AstraZeneca [email protected]

Raphael Chow Strategy Consultant, Monitor Deloitte [email protected]

Ricardo Sanchez Velazquez Undergraduate, University of Glasgow [email protected]

Robert Oppenheimer PhD Candidate, University of Oxford [email protected]

Mr Ross Lindsay PhD Candidate, University of Cambridge [email protected]

Sandhya Sriram Research Fellow, BMSI, A*STAR

[email protected]


2016GapSummit 57

Lead

ers

of T

omor

row

Sandra Giuliani Scientist, AstraZeneca [email protected]

Sanjana Bhaskar M.Phil in Bioscience Enterprise,

University of Cambridge [email protected]

Sebastian Porsdam Mann PhD Candidate,


Sheun Oshinbolu EngD Candidate,

UCL/GSK [email protected]

Summer Park Business Acceleration Advisor,

Callaghan Innovation [email protected]

Dr Teresa Carusone CEO,

Detoxizymes [email protected]

Tianwei Roger Long MPhil Bioscience Enterprise,


Tomaz Bizjak MPhil Candidate,


Tony Olmert M.Phil Bioscience Enterprise,


Vahap Aydogan PhD Candidate,

University of Basel [email protected]

Valérie Hepp Strategic Partnering,

F. Hoffmann-La Roche [email protected]

Victor Bustos PhD Candidate,

MPI for Biology of Ageing [email protected]

Víctor Alejandro Barría Jorquera M.Sc. Candidate,

Universidad de Concepción [email protected]

Dr Vincent Ruland Senior Consultant R&D,

Bayer Business Consulting [email protected]

Emuejevoke T. Toye PhD Candidate,

University of Lagos, Nigeria [email protected]

William H. Marks PhD Candidate,


Yogesh Lakhotia Undergraduate,

Indian Institute of Technology Kharagpur

[email protected]

Extraordinary medicinerequires extraordinary science.

At Roche, we are committed to both. Discovering and developing innovative medicines and diagnostic tests to help people live better, longer lives.

Whatscience can do

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Biologics in the treatment of asthmaEosinophils are known to infiltrate the airways of some asthma patients and cause airway inflammation. AstraZeneca is developing a biologic that binds to the surface of eosinophils and recruits natural killer cells to remove them from circulation.

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.

For more information visit

www.medimmune.com

Pushing the boundaries of

Science

2016GapSummitis kindly hosted by

St. John’s College Cambridge


62

Alise is doing a PhD in Stem Cell Biology at the University of Cambridge and holds an Integrated Master in Science degree

in Genetics from the University of Glasgow. She was one of the Leaders of Tomorrow at the inaugural GapSummit 2014, while

working at GlaxoSmithKline / Domantis.

Gap

Sum

mit

201

6 C

omm

ittee

Anna is studying an MPhil in Bioscience Enterprise at the University of Cambridge, and holds a Master of Process

Engineering from ETH Zurich and a Bachelor of Chemical Engineering from the University of New South Wales. In 2013 she was the winner and a member of the winning team at the

Novartis International Biotechnology Camp in Switzerland. Before switching to engineering, Anna studied music, and is an

accomplished pianist.

Lisa is a Director of Global Biotech Revolution and President of the GapSummit 2016. A graduate in Natural Sciences and

Management Studies from the University of Cambridge, she is currently studying for an MSc in International Health

Policy at the London School of Economics and Social Policy.

Lisa Altmann-RicherPresident

Anna GouldVice President

Alise MoltovaCOO


63

Toryn graduated with an MSci in Natural Sciences(Chemistry) from the University of Cambridge, where he was President of Trinity College Science Society andattended GapSummit 2014. He is now an AssociateScientist at GSK and in the second year of the FutureLeaders Programme. His interests include continuousprocessing and sustainable manufacture of APIs.

Gap

Sum

mit

201

6 C

omm

ittee

Toryn DaltonMarketing Officer

Patrick is reading for a PhD degree in Chemistry at the University of Cambridge working on the elucidation of pro-tein aggregation mechanisms related to neurodegenerative disorders such as Parkinson’s disease. Before he performed research in Stanford (USA) and Munich (Germany). He is interested in Biotechnology, Public Health, Consulting and Sport.

Patrick FlagmeierMedia Officer

Sandy is an experienced molecular biological scientist with multidisciplinary hands-on business experience in start-ups and healthcare consulting. She is passionate about biotech-nology development and has led influential and diverse stakeholder organisations. Currently she is a MPhil in Biosci-ence Enterprise student at the University of Cambridge.

Sandy TungVoT Coordinator


64

Currently, Fabio is a Master's student in Bioscience En-terprise at the University of Cambridge, where he stud-

ies the commercial, legal and regulatory issues associated with bringing biotechnology advances to market. He has a Bachelor’s degree in Biotechnology from the Università degli Studi di Trento and participated at the international

synthetic biology competition iGEM held at MIT.

Markus is a bioinformatics consultant working in the fields of cancer genomics and infectious fungal diseases. He holds a PhD in Computational Infection Biology from University

College Dublin, Ireland. He worked as a bioinformatician at the Dana-Farber Cancer Institute, Boston and completed

a summer internship in the Next Generation Sequencing Department at Genentech, South San Francisco.

Markus SchröderLoT Liaison

Gap

Sum

mit

201

6 C

omm

ittee

Fabio DigiacomoSpeakers Liaison

A graduate in Computer Systems from the University of Auckland, he is currently working in the banking sector in London, and loves to make future travel plans around

Europe in his spare time.

Croydon Dias Webmaster


65

Karol FiedorczukLogistics Team

Elly SetiawayLogistics Team

Aurélie DeleforgeLogistics Team

Gap

Sum

mit

201

6 C

omm

ittee

Karol is a Cambridge University PhD student, currently con-tinuing his research at the Institute of Science and Technol-ogy in Austria. He obtained a Master’s degree in Biotechnol-ogy awarded by Maria Curie-Sklodowska University and Polish Academy of Sciences. His scientific interest lies in the field of structural and molecular biology.

Elly is a Master’s student in Bioscience Enterprise at the University of Cambridge She is an awardee of the Indonesia Endowment Fund for Education (LPDP). Her experiences include working in two veterinary pharmaceu-tical companies in Indonesia to develop feed enzymes and animal vaccines. She is interested in the business aspects of life science.

From the Ecole Polytechnique in France, Aurélie has a mathematics, physics and bioengineering background and is studying an MPhil in Bioscience Enterprise at the University of Cambridge. She plans to start her career in life science consulting.


66

GBR

Exe

cuti

ve T

eam

Ipshita MandalCo-Founder &

President

In 2012 Ipshita founded Global Biotech Revolution and led the first GapSummit. She is currently leading the scientific

and business development strategy at a Cambridge based biotech, Bactevo. She grew up in India, Kenya, New Zealand

and Singapore and has won multiple awards in grand chal-lenges debate, entrepreneurship and innovation.

Christian GuyaderCo-Founder & Vice President

Christian co-founded Global Biotech Revolution and co-leads the team with Ipshita. He just finished a PhD at the

University of Cambridge where he looked at peptide medi-ated gene delivery for gene therapy. Christian is now going

to start working as a strategy consultant.

Frieder joined Global Biotech Revolution in 2012 and cur-rently holds the position of the Chief Operating Officer. He

completed his PhD at the University of Cambridge in the field of proteomic biomarker discovery for mental disorders

and gained experience in clinical trails. His special interest is in synthetic biology and visionary technologies like 3D-

printed drugs.

Frieder HaenischCOO


2016GapSummit 67


Thank You

We would like to express special thanks to the Global Biotech Revolution Advisory Board: Sir Gregory Winter, Prof. Chris Lowe, Annalisa Jenkins,

Prof. Christopher Dobson, Tom Saylor and Prof. Gerard Evan.

The GapSummit 2016 would also not have been possible without the in-sights and kind support of our Speakers, Mentors and Sponsors.

We would also like to thank Harsh Vaidya and Carol Ibe for all their work on the GapSummit 2016 project, Rebeka Marton for the support of the Trin-

ity College Science Society, as well as the GapSummit 2016 volunteers for dedicating their time throughout the summit.

We would like to thank our hosts St John’s College as well as the following organisations for their support: A

ckno

wle

dgem

ents

ChiasmaConnectomeLaBiotechOne NucleusSynBioBetaTrinity College Science SocietyYEBN

AstraZenecaMcKinsey & Company

MedImmuneMerck KGaA

PHG FoundationPotter Clarkson

Roche

A final thank you goes to the Global Biotech Revolution Executive Team who were always on hand to guide and support us.


68

Venu

eMain Venue

The GapSummit 2016 is hosted at the Old Divinity School of St John’s College.The main proceedings, including panel debates, discussions, the Voices ofTomorrow competition, tea breaks and lunches will be taking place here.

The St John’s Old Divinity School is situated opposite the Great Gate to St John’s College (see Map on page 71).

Address:Old Divinity School St John’s CollegeSt John’s StreetCambridgeCB2 1TP


2016GapSummit 69


Venu

e

Day 1 Workshops

The workshops will be held at the historic Cambridge Union building, a short walk from the main venue (see map on page 71).

4:15 pm - 5:00 pmWorkshop Session 1

5:10 pm - 5:55 pmWorkshop Session 2

Address:The Cambridge Union Society9A Bridge StreetCambridgeCB2 1UB

Grand Formal Dinner

All speakers and Leaders of Tomorrow are invited to a Grand Formal Din-ner at Trinity College, located on Trinity Street, a short walk from the Old Divinity School (see Map on page 71).

6:00 pm - 7:00 pmPre-dinner drinks in the Master’s Lodge

7:15pm - 10:00 pmThree-course formal dinner in Great Hall withkeynote speaker Sir Leszek Borysiewicz,Vice-Chancellor, University of Cambridge

Dress code: business wear

Address:Trinity CollegeCambridgeCB2 1TQ


70

Venu

e

photograph used by permission of Cambridge Science Park

Day 2 Leaders of Tomorrow Field Trip

The second day of the conference will conclude with a visit to theCambridge Science Park, approximately 3 miles north-east of the main venue. Transport by coach will be provided.

1:00 pm - 2:00 pmLeaders of Tomorrow travel to Cambridge Science Park(coaches depart 1:15 pm from Queen’s Road coach bays)

A packed lunch will be provided.

2:15 pm - 3:00 pmCambridge Science Park Session 1Presentation Session A, Trinity CentrePresentation Session B, Trinity CentreWalking Tour of Cambridge Science Park

We advise you to dress appropriately for the outdoor weather.

3:15 pm - 4:00 pmCambridge Science Park Session 2(As Session 1)4:15 pm - 5:00 pmCambridge Science Park Session 3(As Session 1)

5:00 pm - 6:00 pmNetworking Reception

6:00 pm - 7:00 pmLeaders of Tomorrow return from Cambridge Science Park

Address:Cambridge Science ParkMilton RoadCambridgeCB4 0FZ


2016GapSummit 71

Map

Old Divinity School

The Cambridge Union

Trinity College

Coach Bays, Queen’s Road

1

2

3

4

The Hilton City Centre Hotel

Trinity Hall College

Christ’s College

5

6

7

1

2

3

4

6 7

5

DIAMOND SPONSOR

SUPPORTERS

KNOWLEDGE PARTNER

GOLD SPONSORS

GENERAL SPONSORS

HOST

Documents

Official GapSummit 2016 Online Programme